INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1510894, 'Ibutilide', 'Halothane', 'Major', 'Like other class III antiarrhythmic agents, ibutilide can cause dose-related QT interval prolongation. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'Caution is recommended if ibutilide is used in combination with other drugs that can prolong the QT interval.', NULL, 'Caution is recommended if ibutilide is used in combination with other drugs that can prolong the QT interval. Ibutilide should only be administered in a setting of continuous ECG monitoring and by personnel trained in identification and treatment of acute ventricular arrhythmias, particularly polymorphic ventricular tachycardia such as torsade de pointes.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1510895, 'Idarubicin', 'Ibutilide', 'Major', 'Like other class III antiarrhythmic agents, ibutilide can cause dose-related QT interval prolongation. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'Caution is recommended if ibutilide is used in combination with other drugs that can prolong the QT interval.', NULL, 'Caution is recommended if ibutilide is used in combination with other drugs that can prolong the QT interval. Ibutilide should only be administered in a setting of continuous ECG monitoring and by personnel trained in identification and treatment of acute ventricular arrhythmias, particularly polymorphic ventricular tachycardia such as torsade de pointes.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1510896, 'Iloperidone', 'Ibutilide', 'Major', 'Iloperidone may cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'Coadministration of iloperidone with other drugs that can prolong the QT interval should generally be avoided.', NULL, 'Coadministration of iloperidone with other drugs that can prolong the QT interval should generally be avoided. Caution and clinical monitoring are recommended if concomitant use is required. Patients should have regular ECGs and be monitored for arrhythmias when QT interval is prolonged. Persistent QTc measurements exceeding 500 msec will require suspension of iloperidone therapy and immediate action to correct any concomitant risk factors before resuming treatment.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1510897, 'Imipramine', 'Ibutilide', 'Major', 'Like other class III antiarrhythmic agents, ibutilide can cause dose-related QT interval prolongation. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'Caution is recommended if ibutilide is used in combination with other drugs that can prolong the QT interval.', NULL, 'Caution is recommended if ibutilide is used in combination with other drugs that can prolong the QT interval. Ibutilide should only be administered in a setting of continuous ECG monitoring and by personnel trained in identification and treatment of acute ventricular arrhythmias, particularly polymorphic ventricular tachycardia such as torsade de pointes.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1510898, 'Indacaterol', 'Ibutilide', 'Moderate', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1510899, 'Iodipamide', 'Ibutilide', 'Moderate', 'The use of iodine-containing contrast media for coronary angiography in patients treated with certain antiarrhythmics such as amiodarone may result in significant prolongation of the QT interval. These contrast agents can be arrhythmogenic when injected into the coronary arteries and may have additive effects on cardiac repolarization when coadministered with antiarrhythmic agents that prolong the QT interval.', NULL, 'Caution is advised if iodine-containing contrast media are used for coronary angiography in patients treated with class IA (e.', NULL, 'Caution is advised if iodine-containing contrast media are used for coronary angiography in patients treated with class IA (e.g., disopyramide, quinidine, procainamide) or class III (e.g., amiodarone, dofetilide, ibutilide, sotalol) antiarrhythmic agents. Increased surveillance and ECG monitoring may be appropriate. Patients who receive outpatient angiographies should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of arrhythmia such as dizziness, palpitations, or syncope.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1510900, 'Iodixanol', 'Ibutilide', 'Moderate', 'The use of iodine-containing contrast media for coronary angiography in patients treated with certain antiarrhythmics such as amiodarone may result in significant prolongation of the QT interval. These contrast agents can be arrhythmogenic when injected into the coronary arteries and may have additive effects on cardiac repolarization when coadministered with antiarrhythmic agents that prolong the QT interval.', NULL, 'Caution is advised if iodine-containing contrast media are used for coronary angiography in patients treated with class IA (e.', NULL, 'Caution is advised if iodine-containing contrast media are used for coronary angiography in patients treated with class IA (e.g., disopyramide, quinidine, procainamide) or class III (e.g., amiodarone, dofetilide, ibutilide, sotalol) antiarrhythmic agents. Increased surveillance and ECG monitoring may be appropriate. Patients who receive outpatient angiographies should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of arrhythmia such as dizziness, palpitations, or syncope.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1510901, 'Ioversol', 'Ibutilide', 'Moderate', 'The use of iodine-containing contrast media for coronary angiography in patients treated with certain antiarrhythmics such as amiodarone may result in significant prolongation of the QT interval. These contrast agents can be arrhythmogenic when injected into the coronary arteries and may have additive effects on cardiac repolarization when coadministered with antiarrhythmic agents that prolong the QT interval.', NULL, 'Caution is advised if iodine-containing contrast media are used for coronary angiography in patients treated with class IA (e.', NULL, 'Caution is advised if iodine-containing contrast media are used for coronary angiography in patients treated with class IA (e.g., disopyramide, quinidine, procainamide) or class III (e.g., amiodarone, dofetilide, ibutilide, sotalol) antiarrhythmic agents. Increased surveillance and ECG monitoring may be appropriate. Patients who receive outpatient angiographies should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of arrhythmia such as dizziness, palpitations, or syncope.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1510902, 'Ioxilan', 'Ibutilide', 'Moderate', 'The use of iodine-containing contrast media for coronary angiography in patients treated with certain antiarrhythmics such as amiodarone may result in significant prolongation of the QT interval. These contrast agents can be arrhythmogenic when injected into the coronary arteries and may have additive effects on cardiac repolarization when coadministered with antiarrhythmic agents that prolong the QT interval.', NULL, 'Caution is advised if iodine-containing contrast media are used for coronary angiography in patients treated with class IA (e.', NULL, 'Caution is advised if iodine-containing contrast media are used for coronary angiography in patients treated with class IA (e.g., disopyramide, quinidine, procainamide) or class III (e.g., amiodarone, dofetilide, ibutilide, sotalol) antiarrhythmic agents. Increased surveillance and ECG monitoring may be appropriate. Patients who receive outpatient angiographies should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of arrhythmia such as dizziness, palpitations, or syncope.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1510903, 'Isoetharine', 'Ibutilide', 'Moderate', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1510904, 'Ibutilide', 'Levobupivacaine', 'Moderate', 'Amide-type local anesthetics may have additive cardiac effects (e.g., bradycardia, chest pain, heart block, arrhythmias, ECG abnormalities, cardiac arrest) with class III antiarrhythmic agents.', NULL, 'Patients treated with class III antiarrhythmic agents (e.', NULL, 'Patients treated with class III antiarrhythmic agents (e.g., amiodarone, dofetilide, ibutilide, sotalol) should be under close surveillance during administration of amide-type local anesthetics. ECG monitoring should be considered.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1510905, 'Ibutilide', 'Levacetylmethadol', 'Major', 'Levomethadyl acetate may cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. High dosages of levomethadyl acetate alone have been associated with QT interval prolongation and torsade de pointes.', NULL, 'Coadministration of levomethadyl acetate with other drugs that can prolong the QT interval is considered contraindicated.', NULL, 'Coadministration of levomethadyl acetate with other drugs that can prolong the QT interval is considered contraindicated.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1510906, 'Ibutilide', 'Lomefloxacin', 'Major', 'Like other class III antiarrhythmic agents, ibutilide can cause dose-related QT interval prolongation. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'Caution is recommended if ibutilide is used in combination with other drugs that can prolong the QT interval.', NULL, 'Caution is recommended if ibutilide is used in combination with other drugs that can prolong the QT interval. Ibutilide should only be administered in a setting of continuous ECG monitoring and by personnel trained in identification and treatment of acute ventricular arrhythmias, particularly polymorphic ventricular tachycardia such as torsade de pointes.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1510907, 'Ibutilide', 'Magnesium citrate', 'Moderate', 'Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.', NULL, 'Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives.', NULL, 'Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1510908, 'Ibutilide', 'Magnesium hydroxide', 'Moderate', 'Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.', NULL, 'Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives.', NULL, 'Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1510909, 'Ibutilide', 'Mesoridazine', 'Major', 'Mesoridazine can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Mesoridazine overdosage has been associated with ventricular arrhythmias and death. The extent of drug-induced QT prolongation is dependent on the particular drug(s) involved and dosage(s) of the drug(s). In addition, certain agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive parasympatholytic and central nervous system-depressant effects when used in combination with mesoridazine. Excessive parasympatholytic effects may include paralytic ileus, hyperthermia, mydriasis, blurred vision, tachycardia, urinary retention, psychosis, and seizures.', NULL, 'Coadministration of mesoridazine with other drugs that can prolong the QT interval is considered contraindicated.', NULL, 'Coadministration of mesoridazine with other drugs that can prolong the QT interval is considered contraindicated.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1510910, 'Ibutilide', 'Methotrimeprazine', 'Major', 'Like other class III antiarrhythmic agents, ibutilide can cause dose-related QT interval prolongation. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'Caution is recommended if ibutilide is used in combination with other drugs that can prolong the QT interval.', NULL, 'Caution is recommended if ibutilide is used in combination with other drugs that can prolong the QT interval. Ibutilide should only be administered in a setting of continuous ECG monitoring and by personnel trained in identification and treatment of acute ventricular arrhythmias, particularly polymorphic ventricular tachycardia such as torsade de pointes.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1510911, 'Ibutilide', 'Mineral oil', 'Moderate', 'Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.', NULL, 'Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives.', NULL, 'Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1510912, 'Ibutilide', 'Moricizine', 'Major', 'Class I antiarrhythmic agents and ibutilide have additive effects and may potentially prolong cardiac refractoriness.', NULL, 'Class I antiarrhythmic agents should not be given concomitantly with ibutilide or within four hours after ibutilide is given.', NULL, 'Class I antiarrhythmic agents should not be given concomitantly with ibutilide or within four hours after ibutilide is given. In clinical trials, other class I agents were withheld for at least five half-lives prior to ibutilide infusion and for four hours after dosing, but thereafter were allowed at the physician''s discretion.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1510913, 'Ibutilide', 'Papaverine', 'Major', 'Intracoronary administration of papaverine has been associated with QT interval prolongation and torsade de pointes (TdP) arrhythmia. The risk may theoretically increase in patients receiving concomitant medications that can also prolong the QT interval or cause bradycardia. The precise mechanism of papaverine-induced ventricular tachyarrhythmias has not been delineated, but may involve inhibition of potassium currents and prolongation of the action potential duration.', NULL, 'Caution and close monitoring are advised during intracoronary administration of papaverine, particularly in patients receiving concomitant drugs that can prolong the QT interval or cause bradycardia and in patients with other risk factors described above.', NULL, 'Caution and close monitoring are advised during intracoronary administration of papaverine, particularly in patients receiving concomitant drugs that can prolong the QT interval or cause bradycardia and in patients with other risk factors described above.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1510914, 'Ibutilide', 'Perphenazine', 'Major', 'Like other class III antiarrhythmic agents, ibutilide can cause dose-related QT interval prolongation. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'Caution is recommended if ibutilide is used in combination with other drugs that can prolong the QT interval.', NULL, 'Caution is recommended if ibutilide is used in combination with other drugs that can prolong the QT interval. Ibutilide should only be administered in a setting of continuous ECG monitoring and by personnel trained in identification and treatment of acute ventricular arrhythmias, particularly polymorphic ventricular tachycardia such as torsade de pointes.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1510915, 'Ibutilide', 'Phenolphthalein', 'Moderate', 'Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.', NULL, 'Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives.', NULL, 'Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1510916, 'Ibutilide', 'Primaquine', 'Major', 'Like other class III antiarrhythmic agents, ibutilide can cause dose-related QT interval prolongation. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'Caution is recommended if ibutilide is used in combination with other drugs that can prolong the QT interval.', NULL, 'Caution is recommended if ibutilide is used in combination with other drugs that can prolong the QT interval. Ibutilide should only be administered in a setting of continuous ECG monitoring and by personnel trained in identification and treatment of acute ventricular arrhythmias, particularly polymorphic ventricular tachycardia such as torsade de pointes.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1510917, 'Ibutilide', 'Probucol', 'Major', 'Like other class III antiarrhythmic agents, ibutilide can cause dose-related QT interval prolongation. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'Caution is recommended if ibutilide is used in combination with other drugs that can prolong the QT interval.', NULL, 'Caution is recommended if ibutilide is used in combination with other drugs that can prolong the QT interval. Ibutilide should only be administered in a setting of continuous ECG monitoring and by personnel trained in identification and treatment of acute ventricular arrhythmias, particularly polymorphic ventricular tachycardia such as torsade de pointes.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1510918, 'Ibutilide', 'Promazine', 'Major', 'Like other class III antiarrhythmic agents, ibutilide can cause dose-related QT interval prolongation. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'Caution is recommended if ibutilide is used in combination with other drugs that can prolong the QT interval.', NULL, 'Caution is recommended if ibutilide is used in combination with other drugs that can prolong the QT interval. Ibutilide should only be administered in a setting of continuous ECG monitoring and by personnel trained in identification and treatment of acute ventricular arrhythmias, particularly polymorphic ventricular tachycardia such as torsade de pointes.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1510919, 'Ibutilide', 'Quinidine', 'Major', 'Class I antiarrhythmic agents and ibutilide have additive effects and may potentially prolong cardiac refractoriness.', NULL, 'Class I antiarrhythmic agents should not be given concomitantly with ibutilide or within four hours after ibutilide is given.', NULL, 'Class I antiarrhythmic agents should not be given concomitantly with ibutilide or within four hours after ibutilide is given. In clinical trials, other class I agents were withheld for at least five half-lives prior to ibutilide infusion and for four hours after dosing, but thereafter were allowed at the physician''s discretion.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1510920, 'Ibutilide', 'Relugolix', 'Major', 'Like other class III antiarrhythmic agents, ibutilide can cause dose-related QT interval prolongation. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'Caution is recommended if ibutilide is used in combination with other drugs that can prolong the QT interval.', NULL, 'Caution is recommended if ibutilide is used in combination with other drugs that can prolong the QT interval. Ibutilide should only be administered in a setting of continuous ECG monitoring and by personnel trained in identification and treatment of acute ventricular arrhythmias, particularly polymorphic ventricular tachycardia such as torsade de pointes.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1510921, 'Ibutilide', 'Ritodrine', 'Major', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'Caution is advised if beta-2 adrenergic agonists are used in combination with other drugs that prolong the QT interval, including class IA and III antiarrhythmic agents, certain neuroleptic agents, phenothiazines, tricyclic antidepressants, quinolones, ketolide and macrolide antibiotics, and cisapride.', NULL, 'Caution is advised if beta-2 adrenergic agonists are used in combination with other drugs that prolong the QT interval, including class IA and III antiarrhythmic agents, certain neuroleptic agents, phenothiazines, tricyclic antidepressants, quinolones, ketolide and macrolide antibiotics, and cisapride. It may be appropriate to monitor ECG and serum electrolytes during chronic systemic use or high-dose therapy. Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitations, irregular heartbeat, shortness of breath, or syncope.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1510922, 'Ibutilide', 'Sparfloxacin', 'Major', 'Sparfloxacin may cause dose-related prolongation of the QT interval in some patients. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'Coadministration of sparfloxacin with other drugs that can prolong the QT interval is considered contraindicated.', NULL, 'Coadministration of sparfloxacin with other drugs that can prolong the QT interval is considered contraindicated.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1510923, 'Ibutilide', 'Tacrine', 'Moderate', 'Acetylcholinesterase inhibitors may have vagotonic effects on the sinoatrial and atrioventricular nodes, which occasionally manifest as bradycardia or heart block (<2%). Because bradycardia is a risk factor for torsade de pointes, a theoretical risk exists when combined with agents that prolong the QT interval.', NULL, 'Caution is advised when acetylcholinesterase inhibitors are used with drugs that can prolong the QT interval.', NULL, 'Caution is advised when acetylcholinesterase inhibitors are used with drugs that can prolong the QT interval. Patients should be monitored for bradycardia, atrioventricular block and syncope, and advised to seek medical attention if they experience dizziness, lightheadedness, fainting, shortness of breath, or slow or irregular heartbeat.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1510924, 'Ibutilide', 'Terbutaline', 'Major', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'Caution is advised if beta-2 adrenergic agonists are used in combination with other drugs that prolong the QT interval, including class IA and III antiarrhythmic agents, certain neuroleptic agents, phenothiazines, tricyclic antidepressants, quinolones, ketolide and macrolide antibiotics, and cisapride.', NULL, 'Caution is advised if beta-2 adrenergic agonists are used in combination with other drugs that prolong the QT interval, including class IA and III antiarrhythmic agents, certain neuroleptic agents, phenothiazines, tricyclic antidepressants, quinolones, ketolide and macrolide antibiotics, and cisapride. It may be appropriate to monitor ECG and serum electrolytes during chronic systemic use or high-dose therapy. Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitations, irregular heartbeat, shortness of breath, or syncope.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1510925, 'Ibutilide', 'Terfenadine', 'Major', 'Like other class III antiarrhythmic agents, ibutilide can cause dose-related QT interval prolongation. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'Caution is recommended if ibutilide is used in combination with other drugs that can prolong the QT interval.', NULL, 'Caution is recommended if ibutilide is used in combination with other drugs that can prolong the QT interval. Ibutilide should only be administered in a setting of continuous ECG monitoring and by personnel trained in identification and treatment of acute ventricular arrhythmias, particularly polymorphic ventricular tachycardia such as torsade de pointes.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1510926, 'Ibutilide', 'Thioridazine', 'Major', 'Thioridazine can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, certain agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive parasympatholytic and central nervous system-depressant effects when used in combination with thioridazine. Excessive parasympatholytic effects may include paralytic ileus, hyperthermia, mydriasis, blurred vision, tachycardia, urinary retention, psychosis, and seizures.', NULL, 'Coadministration of thioridazine with other drugs that can prolong the QT interval is considered contraindicated.', NULL, 'Coadministration of thioridazine with other drugs that can prolong the QT interval is considered contraindicated.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1510927, 'Ibutilide', 'Trifluoperazine', 'Major', 'Like other class III antiarrhythmic agents, ibutilide can cause dose-related QT interval prolongation. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'Caution is recommended if ibutilide is used in combination with other drugs that can prolong the QT interval.', NULL, 'Caution is recommended if ibutilide is used in combination with other drugs that can prolong the QT interval. Ibutilide should only be administered in a setting of continuous ECG monitoring and by personnel trained in identification and treatment of acute ventricular arrhythmias, particularly polymorphic ventricular tachycardia such as torsade de pointes.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1510928, 'Ibutilide', 'Triflupromazine', 'Major', 'Like other class III antiarrhythmic agents, ibutilide can cause dose-related QT interval prolongation. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'Caution is recommended if ibutilide is used in combination with other drugs that can prolong the QT interval.', NULL, 'Caution is recommended if ibutilide is used in combination with other drugs that can prolong the QT interval. Ibutilide should only be administered in a setting of continuous ECG monitoring and by personnel trained in identification and treatment of acute ventricular arrhythmias, particularly polymorphic ventricular tachycardia such as torsade de pointes.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1510929, 'Ibutilide', 'Alimemazine', 'Major', 'Like other class III antiarrhythmic agents, ibutilide can cause dose-related QT interval prolongation. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'Caution is recommended if ibutilide is used in combination with other drugs that can prolong the QT interval.', NULL, 'Caution is recommended if ibutilide is used in combination with other drugs that can prolong the QT interval. Ibutilide should only be administered in a setting of continuous ECG monitoring and by personnel trained in identification and treatment of acute ventricular arrhythmias, particularly polymorphic ventricular tachycardia such as torsade de pointes.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1510930, 'Anisindione', 'Icosapent', 'Moderate', 'Omega-3 fatty acids (e.g., fish oil) may potentiate the pharmacologic effects of anticoagulants and other drugs that affect hemostasis such as platelet inhibitors, thrombin inhibitors, thrombolytic agents, dextran, and nonsteroidal anti-inflammatory drugs (NSAIDs). The exact mechanism of interaction is unknown. Omega-3 fatty acids may possess mild antiplatelet and hypocoagulant activities.', NULL, 'In general, patients should consult a healthcare provider before taking any herbal or nutritional supplements.', NULL, 'In general, patients should consult a healthcare provider before taking any herbal or nutritional supplements. Patients using omega-3 fatty acids in combination with anticoagulants or other drugs that affect hemostasis should be advised of the potential for increased risk of bleeding complications.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1510931, 'Anistreplase', 'Icosapent', 'Moderate', 'Omega-3 fatty acids (e.g., fish oil) may potentiate the pharmacologic effects of anticoagulants and other drugs that affect hemostasis such as platelet inhibitors, thrombin inhibitors, thrombolytic agents, dextran, and nonsteroidal anti-inflammatory drugs (NSAIDs). The exact mechanism of interaction is unknown. Omega-3 fatty acids may possess mild antiplatelet and hypocoagulant activities.', NULL, 'In general, patients should consult a healthcare provider before taking any herbal or nutritional supplements.', NULL, 'In general, patients should consult a healthcare provider before taking any herbal or nutritional supplements. Patients using omega-3 fatty acids in combination with anticoagulants or other drugs that affect hemostasis should be advised of the potential for increased risk of bleeding complications.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1510932, 'Icosapent', 'Ardeparin', 'Moderate', 'Omega-3 fatty acids (e.g., fish oil) may potentiate the pharmacologic effects of anticoagulants and other drugs that affect hemostasis such as platelet inhibitors, thrombin inhibitors, thrombolytic agents, dextran, and nonsteroidal anti-inflammatory drugs (NSAIDs). The exact mechanism of interaction is unknown. Omega-3 fatty acids may possess mild antiplatelet and hypocoagulant activities.', NULL, 'In general, patients should consult a healthcare provider before taking any herbal or nutritional supplements.', NULL, 'In general, patients should consult a healthcare provider before taking any herbal or nutritional supplements. Patients using omega-3 fatty acids in combination with anticoagulants or other drugs that affect hemostasis should be advised of the potential for increased risk of bleeding complications.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1510933, 'Icosapent', 'Argatroban', 'Moderate', 'Omega-3 fatty acids (e.g., fish oil) may potentiate the pharmacologic effects of anticoagulants and other drugs that affect hemostasis such as platelet inhibitors, thrombin inhibitors, thrombolytic agents, dextran, and nonsteroidal anti-inflammatory drugs (NSAIDs). The exact mechanism of interaction is unknown. Omega-3 fatty acids may possess mild antiplatelet and hypocoagulant activities.', NULL, 'In general, patients should consult a healthcare provider before taking any herbal or nutritional supplements.', NULL, 'In general, patients should consult a healthcare provider before taking any herbal or nutritional supplements. Patients using omega-3 fatty acids in combination with anticoagulants or other drugs that affect hemostasis should be advised of the potential for increased risk of bleeding complications.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1510934, 'Icosapent', 'Bromfenac', 'Moderate', 'Omega-3 fatty acids (e.g., fish oil) may potentiate the pharmacologic effects of anticoagulants and other drugs that affect hemostasis such as platelet inhibitors, thrombin inhibitors, thrombolytic agents, dextran, and nonsteroidal anti-inflammatory drugs (NSAIDs). The exact mechanism of interaction is unknown. Omega-3 fatty acids may possess mild antiplatelet and hypocoagulant activities.', NULL, 'In general, patients should consult a healthcare provider before taking any herbal or nutritional supplements.', NULL, 'In general, patients should consult a healthcare provider before taking any herbal or nutritional supplements. Patients using omega-3 fatty acids in combination with anticoagulants or other drugs that affect hemostasis should be advised of the potential for increased risk of bleeding complications.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1510935, 'Icosapent', 'Danaparoid', 'Moderate', 'Omega-3 fatty acids (e.g., fish oil) may potentiate the pharmacologic effects of anticoagulants and other drugs that affect hemostasis such as platelet inhibitors, thrombin inhibitors, thrombolytic agents, dextran, and nonsteroidal anti-inflammatory drugs (NSAIDs). The exact mechanism of interaction is unknown. Omega-3 fatty acids may possess mild antiplatelet and hypocoagulant activities.', NULL, 'In general, patients should consult a healthcare provider before taking any herbal or nutritional supplements.', NULL, 'In general, patients should consult a healthcare provider before taking any herbal or nutritional supplements. Patients using omega-3 fatty acids in combination with anticoagulants or other drugs that affect hemostasis should be advised of the potential for increased risk of bleeding complications.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1510936, 'Icosapent', 'Dextran (-1)', 'Moderate', 'Omega-3 fatty acids (e.g., fish oil) may potentiate the pharmacologic effects of anticoagulants and other drugs that affect hemostasis such as platelet inhibitors, thrombin inhibitors, thrombolytic agents, dextran, and nonsteroidal anti-inflammatory drugs (NSAIDs). The exact mechanism of interaction is unknown. Omega-3 fatty acids may possess mild antiplatelet and hypocoagulant activities.', NULL, 'In general, patients should consult a healthcare provider before taking any herbal or nutritional supplements.', NULL, 'In general, patients should consult a healthcare provider before taking any herbal or nutritional supplements. Patients using omega-3 fatty acids in combination with anticoagulants or other drugs that affect hemostasis should be advised of the potential for increased risk of bleeding complications.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1510937, 'Icosapent', 'Dextran (high molecular weight)', 'Moderate', 'Omega-3 fatty acids (e.g., fish oil) may potentiate the pharmacologic effects of anticoagulants and other drugs that affect hemostasis such as platelet inhibitors, thrombin inhibitors, thrombolytic agents, dextran, and nonsteroidal anti-inflammatory drugs (NSAIDs). The exact mechanism of interaction is unknown. Omega-3 fatty acids may possess mild antiplatelet and hypocoagulant activities.', NULL, 'In general, patients should consult a healthcare provider before taking any herbal or nutritional supplements.', NULL, 'In general, patients should consult a healthcare provider before taking any herbal or nutritional supplements. Patients using omega-3 fatty acids in combination with anticoagulants or other drugs that affect hemostasis should be advised of the potential for increased risk of bleeding complications.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1510938, 'Icosapent', 'Dicoumarol', 'Moderate', 'Omega-3 fatty acids (e.g., fish oil) may potentiate the pharmacologic effects of anticoagulants and other drugs that affect hemostasis such as platelet inhibitors, thrombin inhibitors, thrombolytic agents, dextran, and nonsteroidal anti-inflammatory drugs (NSAIDs). The exact mechanism of interaction is unknown. Omega-3 fatty acids may possess mild antiplatelet and hypocoagulant activities.', NULL, 'In general, patients should consult a healthcare provider before taking any herbal or nutritional supplements.', NULL, 'In general, patients should consult a healthcare provider before taking any herbal or nutritional supplements. Patients using omega-3 fatty acids in combination with anticoagulants or other drugs that affect hemostasis should be advised of the potential for increased risk of bleeding complications.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1510939, 'Icosapent', 'Diflunisal', 'Moderate', 'Omega-3 fatty acids (e.g., fish oil) may potentiate the pharmacologic effects of anticoagulants and other drugs that affect hemostasis such as platelet inhibitors, thrombin inhibitors, thrombolytic agents, dextran, and nonsteroidal anti-inflammatory drugs (NSAIDs). The exact mechanism of interaction is unknown. Omega-3 fatty acids may possess mild antiplatelet and hypocoagulant activities.', NULL, 'In general, patients should consult a healthcare provider before taking any herbal or nutritional supplements.', NULL, 'In general, patients should consult a healthcare provider before taking any herbal or nutritional supplements. Patients using omega-3 fatty acids in combination with anticoagulants or other drugs that affect hemostasis should be advised of the potential for increased risk of bleeding complications.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1510940, 'Icosapent', 'Drotrecogin alfa', 'Moderate', 'Omega-3 fatty acids (e.g., fish oil) may potentiate the pharmacologic effects of anticoagulants and other drugs that affect hemostasis such as platelet inhibitors, thrombin inhibitors, thrombolytic agents, dextran, and nonsteroidal anti-inflammatory drugs (NSAIDs). The exact mechanism of interaction is unknown. Omega-3 fatty acids may possess mild antiplatelet and hypocoagulant activities.', NULL, 'In general, patients should consult a healthcare provider before taking any herbal or nutritional supplements.', NULL, 'In general, patients should consult a healthcare provider before taking any herbal or nutritional supplements. Patients using omega-3 fatty acids in combination with anticoagulants or other drugs that affect hemostasis should be advised of the potential for increased risk of bleeding complications.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1510941, 'Icosapent', 'Heparin', 'Moderate', 'Omega-3 fatty acids (e.g., fish oil) may potentiate the pharmacologic effects of anticoagulants and other drugs that affect hemostasis such as platelet inhibitors, thrombin inhibitors, thrombolytic agents, dextran, and nonsteroidal anti-inflammatory drugs (NSAIDs). The exact mechanism of interaction is unknown. Omega-3 fatty acids may possess mild antiplatelet and hypocoagulant activities.', NULL, 'In general, patients should consult a healthcare provider before taking any herbal or nutritional supplements.', NULL, 'In general, patients should consult a healthcare provider before taking any herbal or nutritional supplements. Patients using omega-3 fatty acids in combination with anticoagulants or other drugs that affect hemostasis should be advised of the potential for increased risk of bleeding complications.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1510942, 'Iloprost', 'Icosapent', 'Moderate', 'Omega-3 fatty acids (e.g., fish oil) may potentiate the pharmacologic effects of anticoagulants and other drugs that affect hemostasis such as platelet inhibitors, thrombin inhibitors, thrombolytic agents, dextran, and nonsteroidal anti-inflammatory drugs (NSAIDs). The exact mechanism of interaction is unknown. Omega-3 fatty acids may possess mild antiplatelet and hypocoagulant activities.', NULL, 'In general, patients should consult a healthcare provider before taking any herbal or nutritional supplements.', NULL, 'In general, patients should consult a healthcare provider before taking any herbal or nutritional supplements. Patients using omega-3 fatty acids in combination with anticoagulants or other drugs that affect hemostasis should be advised of the potential for increased risk of bleeding complications.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1510943, 'Indomethacin', 'Icosapent', 'Moderate', 'Omega-3 fatty acids (e.g., fish oil) may potentiate the pharmacologic effects of anticoagulants and other drugs that affect hemostasis such as platelet inhibitors, thrombin inhibitors, thrombolytic agents, dextran, and nonsteroidal anti-inflammatory drugs (NSAIDs). The exact mechanism of interaction is unknown. Omega-3 fatty acids may possess mild antiplatelet and hypocoagulant activities.', NULL, 'In general, patients should consult a healthcare provider before taking any herbal or nutritional supplements.', NULL, 'In general, patients should consult a healthcare provider before taking any herbal or nutritional supplements. Patients using omega-3 fatty acids in combination with anticoagulants or other drugs that affect hemostasis should be advised of the potential for increased risk of bleeding complications.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1510944, 'Icosapent', 'Lepirudin', 'Moderate', 'Omega-3 fatty acids (e.g., fish oil) may potentiate the pharmacologic effects of anticoagulants and other drugs that affect hemostasis such as platelet inhibitors, thrombin inhibitors, thrombolytic agents, dextran, and nonsteroidal anti-inflammatory drugs (NSAIDs). The exact mechanism of interaction is unknown. Omega-3 fatty acids may possess mild antiplatelet and hypocoagulant activities.', NULL, 'In general, patients should consult a healthcare provider before taking any herbal or nutritional supplements.', NULL, 'In general, patients should consult a healthcare provider before taking any herbal or nutritional supplements. Patients using omega-3 fatty acids in combination with anticoagulants or other drugs that affect hemostasis should be advised of the potential for increased risk of bleeding complications.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1510945, 'Icosapent', 'Meclofenamic acid', 'Moderate', 'Omega-3 fatty acids (e.g., fish oil) may potentiate the pharmacologic effects of anticoagulants and other drugs that affect hemostasis such as platelet inhibitors, thrombin inhibitors, thrombolytic agents, dextran, and nonsteroidal anti-inflammatory drugs (NSAIDs). The exact mechanism of interaction is unknown. Omega-3 fatty acids may possess mild antiplatelet and hypocoagulant activities.', NULL, 'In general, patients should consult a healthcare provider before taking any herbal or nutritional supplements.', NULL, 'In general, patients should consult a healthcare provider before taking any herbal or nutritional supplements. Patients using omega-3 fatty acids in combination with anticoagulants or other drugs that affect hemostasis should be advised of the potential for increased risk of bleeding complications.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1510946, 'Icosapent', 'Phenylbutazone', 'Moderate', 'Omega-3 fatty acids (e.g., fish oil) may potentiate the pharmacologic effects of anticoagulants and other drugs that affect hemostasis such as platelet inhibitors, thrombin inhibitors, thrombolytic agents, dextran, and nonsteroidal anti-inflammatory drugs (NSAIDs). The exact mechanism of interaction is unknown. Omega-3 fatty acids may possess mild antiplatelet and hypocoagulant activities.', NULL, 'In general, patients should consult a healthcare provider before taking any herbal or nutritional supplements.', NULL, 'In general, patients should consult a healthcare provider before taking any herbal or nutritional supplements. Patients using omega-3 fatty acids in combination with anticoagulants or other drugs that affect hemostasis should be advised of the potential for increased risk of bleeding complications.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1510947, 'Icosapent', 'Streptokinase', 'Moderate', 'Omega-3 fatty acids (e.g., fish oil) may potentiate the pharmacologic effects of anticoagulants and other drugs that affect hemostasis such as platelet inhibitors, thrombin inhibitors, thrombolytic agents, dextran, and nonsteroidal anti-inflammatory drugs (NSAIDs). The exact mechanism of interaction is unknown. Omega-3 fatty acids may possess mild antiplatelet and hypocoagulant activities.', NULL, 'In general, patients should consult a healthcare provider before taking any herbal or nutritional supplements.', NULL, 'In general, patients should consult a healthcare provider before taking any herbal or nutritional supplements. Patients using omega-3 fatty acids in combination with anticoagulants or other drugs that affect hemostasis should be advised of the potential for increased risk of bleeding complications.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1510948, 'Icosapent', 'Sulfinpyrazone', 'Moderate', 'Omega-3 fatty acids (e.g., fish oil) may potentiate the pharmacologic effects of anticoagulants and other drugs that affect hemostasis such as platelet inhibitors, thrombin inhibitors, thrombolytic agents, dextran, and nonsteroidal anti-inflammatory drugs (NSAIDs). The exact mechanism of interaction is unknown. Omega-3 fatty acids may possess mild antiplatelet and hypocoagulant activities.', NULL, 'In general, patients should consult a healthcare provider before taking any herbal or nutritional supplements.', NULL, 'In general, patients should consult a healthcare provider before taking any herbal or nutritional supplements. Patients using omega-3 fatty acids in combination with anticoagulants or other drugs that affect hemostasis should be advised of the potential for increased risk of bleeding complications.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1510949, 'Icosapent', 'Tinzaparin', 'Moderate', 'Omega-3 fatty acids (e.g., fish oil) may potentiate the pharmacologic effects of anticoagulants and other drugs that affect hemostasis such as platelet inhibitors, thrombin inhibitors, thrombolytic agents, dextran, and nonsteroidal anti-inflammatory drugs (NSAIDs). The exact mechanism of interaction is unknown. Omega-3 fatty acids may possess mild antiplatelet and hypocoagulant activities.', NULL, 'In general, patients should consult a healthcare provider before taking any herbal or nutritional supplements.', NULL, 'In general, patients should consult a healthcare provider before taking any herbal or nutritional supplements. Patients using omega-3 fatty acids in combination with anticoagulants or other drugs that affect hemostasis should be advised of the potential for increased risk of bleeding complications.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1510950, 'Icosapent', 'Tolmetin', 'Moderate', 'Omega-3 fatty acids (e.g., fish oil) may potentiate the pharmacologic effects of anticoagulants and other drugs that affect hemostasis such as platelet inhibitors, thrombin inhibitors, thrombolytic agents, dextran, and nonsteroidal anti-inflammatory drugs (NSAIDs). The exact mechanism of interaction is unknown. Omega-3 fatty acids may possess mild antiplatelet and hypocoagulant activities.', NULL, 'In general, patients should consult a healthcare provider before taking any herbal or nutritional supplements.', NULL, 'In general, patients should consult a healthcare provider before taking any herbal or nutritional supplements. Patients using omega-3 fatty acids in combination with anticoagulants or other drugs that affect hemostasis should be advised of the potential for increased risk of bleeding complications.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1510951, 'Icosapent', 'Urokinase', 'Moderate', 'Omega-3 fatty acids (e.g., fish oil) may potentiate the pharmacologic effects of anticoagulants and other drugs that affect hemostasis such as platelet inhibitors, thrombin inhibitors, thrombolytic agents, dextran, and nonsteroidal anti-inflammatory drugs (NSAIDs). The exact mechanism of interaction is unknown. Omega-3 fatty acids may possess mild antiplatelet and hypocoagulant activities.', NULL, 'In general, patients should consult a healthcare provider before taking any herbal or nutritional supplements.', NULL, 'In general, patients should consult a healthcare provider before taking any herbal or nutritional supplements. Patients using omega-3 fatty acids in combination with anticoagulants or other drugs that affect hemostasis should be advised of the potential for increased risk of bleeding complications.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1510952, 'Idarubicin', 'Abarelix', 'Moderate', 'Long-term androgen deprivation therapy can prolong the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, the extent of drug-induced QT prolongation is dependent on the particular drug(s) involved and dosage(s) of the drug(s).', NULL, 'The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.', NULL, 'The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval. Electrolyte abnormalities should be corrected prior to initiating therapy, and periodic monitoring of electrocardiograms and electrolytes should be considered.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1510953, 'Idarubicin', 'Human adenovirus e serotype 4 strain cl-68578 antigen', 'Moderate', 'There are no data regarding the use of live, unattenuated Adenovirus Type 4 and Type 7 vaccine during treatment with immunosuppressive therapies, including alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids. It is not known whether immunosuppressed patients may have an increased risk of adverse reactions or a decreased or suboptimal immunologic response to the vaccine.', NULL, 'The safety and efficacy of live, unattenuated Adenovirus Type 4 and Type 7 vaccine have not been established in patients receiving immunosuppressive therapies.', NULL, 'The safety and efficacy of live, unattenuated Adenovirus Type 4 and Type 7 vaccine have not been established in patients receiving immunosuppressive therapies. Caution is advised.', 'Others', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1510954, 'Idarubicin', 'Amoxapine', 'Moderate', 'Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.', NULL, 'Caution and clinical monitoring are recommended.', NULL, 'Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1510955, 'Idarubicin', 'Astemizole', 'Moderate', 'Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.', NULL, 'Caution and clinical monitoring are recommended.', NULL, 'Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1510956, 'Idarubicin', 'Bacillus calmette-guerin substrain tice live antigen', 'Major', 'The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids. These patients may also have increased adverse reactions and decreased or suboptimal immunologic response to vaccines.', NULL, 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.', NULL, 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide). Current local immunization guidelines should be consulted for recommendations.', 'Others', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1510957, 'Idarubicin', 'Bedaquiline', 'Major', 'Bedaquiline can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'Caution is recommended if bedaquiline is used in combination with other drugs that can prolong the QT interval.', NULL, 'Caution is recommended if bedaquiline is used in combination with other drugs that can prolong the QT interval. ECG and serum electrolytes, including potassium, magnesium and calcium, should be monitored before starting bedaquiline therapy and periodically during treatment in accordance with the product labeling. Hypokalemia, hypomagnesemia, and hypocalcemia must be corrected prior to bedaquiline administration.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1510958, 'Idarubicin', 'Bepridil', 'Major', 'Class IA (e.g., disopyramide, quinidine, procainamide) and class III (e.g., amiodarone, dofetilide, sotalol) antiarrhythmic agents can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'Coadministration of class IA or class III antiarrhythmic agents with other drugs that can prolong the QT interval should preferably be avoided unless benefits are anticipated to outweigh the risks.', NULL, 'Coadministration of class IA or class III antiarrhythmic agents with other drugs that can prolong the QT interval should preferably be avoided unless benefits are anticipated to outweigh the risks. Caution and clinical monitoring are recommended if concomitant use is required. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1510959, 'Idarubicin', 'Bifidobacterium longum infantis', 'Moderate', 'Probiotic use during immunosuppressant or intense antineoplastic therapy may theoretically increase the risk of infections from the live microorganisms contained in probiotic products. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.', NULL, 'Caution is advised when probiotics are used during immunosuppressant or intense antineoplastic therapy.', NULL, 'Caution is advised when probiotics are used during immunosuppressant or intense antineoplastic therapy. It may be advisable to avoid using probiotics, particularly products containing saccharomyces boulardii, in patients who are significantly immunosuppressed.', 'Others', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1510960, 'Idarubicin', 'Boceprevir', 'Moderate', 'Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of daunorubicin and idarubicin, both of which are substrates of the efflux transporter also known as ABCB1 or MDR1. The interaction has been studied with cyclosporine, a potent P-gp inhibitor, in attempt to overcome multidrug resistance in MDR1-overexpressing tumors.', NULL, 'Caution is advised if daunorubicin or idarubicin is prescribed in combination with a P-gp inhibitor.', NULL, 'Caution is advised if daunorubicin or idarubicin is prescribed in combination with a P-gp inhibitor. Patients should be closely monitored for increased adverse effects including cardiotoxicity and myelosuppression.', 'Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1510961, 'Idarubicin', 'Candida albicans', 'Moderate', 'Immunosuppressed patients may have diminished response to diagnostic skin test antigens due to suppression of cell-mediated, delayed-type hypersensitivity. Falsely insignificant or false-negative results may occur in such patients, which may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.', NULL, 'Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.', NULL, 'Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.', 'Others', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1510962, 'Idarubicin', 'Chlorpromazine', 'Moderate', 'Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.', NULL, 'Caution and clinical monitoring are recommended.', NULL, 'Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1510963, 'Idarubicin', 'Vibrio cholerae CVD 103-HgR strain live antigen', 'Moderate', 'The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.', NULL, 'In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.', NULL, 'In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin''s disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.', 'Antagonism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1510964, 'Idarubicin', 'Cinoxacin', 'Minor', 'Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics. The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.', NULL, '-', NULL, '-', 'Absorption', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1510965, 'Idarubicin', 'Cisapride', 'Major', 'Cisapride can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'Coadministration of cisapride with other drugs that can prolong the QT interval is considered contraindicated.', NULL, 'Coadministration of cisapride with other drugs that can prolong the QT interval is considered contraindicated.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1510966, 'Idarubicin', 'Coccidioides immitis spherule', 'Moderate', 'Immunosuppressed patients may have diminished response to diagnostic skin test antigens due to suppression of cell-mediated, delayed-type hypersensitivity. Falsely insignificant or false-negative results may occur in such patients, which may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.', NULL, 'Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.', NULL, 'Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.', 'Others', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1510967, 'Idarubicin', 'Cytarabine', 'Moderate', 'The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.', NULL, 'Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.', NULL, 'Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers'' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1510968, 'Idarubicin', 'Cytarabine (liposomal)', 'Moderate', 'The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.', NULL, 'Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.', NULL, 'Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers'' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1510969, 'Idarubicin', 'Dacarbazine', 'Moderate', 'The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.', NULL, 'Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.', NULL, 'Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers'' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1510970, 'Idarubicin', 'Doxorubicin (liposomal)', 'Moderate', 'Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.', NULL, 'Caution and clinical monitoring are recommended.', NULL, 'Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1510971, 'Idarubicin', 'Efalizumab', 'Moderate', 'The use of efalizumab with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Efalizumab alone can cause serious infections requiring hospitalization, and the risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'The safety and efficacy of efalizumab in combination with other immunosuppressive agents or phototherapy have not been evaluated.', NULL, 'The safety and efficacy of efalizumab in combination with other immunosuppressive agents or phototherapy have not been evaluated. Patients receiving other immunosuppressive agents should not be treated with efalizumab because of the possibility of excessive immunosuppression. The duration of the period following treatment with efalizumab before one should consider starting other immunosuppressive therapy has not been evaluated.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1510972, 'Idarubicin', 'Enoxacin', 'Minor', 'Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics. The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.', NULL, '-', NULL, '-', 'Absorption', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1510973, 'Idarubicin', 'Gatifloxacin', 'Major', 'Certain quinolones, including gatifloxacin and moxifloxacin, may cause dose-related prolongation of the QT interval in some patients. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, the extent of drug-induced QT prolongation is dependent on the particular drug(s) involved and dosage(s) of the drug(s).', NULL, 'Coadministration of gatifloxacin or moxifloxacin with other drugs that can prolong the QT interval should generally be avoided.', NULL, 'Coadministration of gatifloxacin or moxifloxacin with other drugs that can prolong the QT interval should generally be avoided. Caution and clinical monitoring are recommended if concomitant use is required. Since the magnitude of QTc prolongation increases with increasing plasma concentrations of the quinolone, recommended dosages and intravenous infusion rates should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1510974, 'Idarubicin', 'Grepafloxacin', 'Major', 'Grepafloxacin can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'Coadministration of grepafloxacin with other drugs that can prolong the QT interval is considered contraindicated.', NULL, 'Coadministration of grepafloxacin with other drugs that can prolong the QT interval is considered contraindicated.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1510975, 'Idarubicin', 'Halofantrine', 'Major', 'Halofantrine can cause dose-related prolongation of the QT interval at recommended therapeutic doses. QTc interval prolongation and death have been reported during combination use of halofantrine and mefloquine. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'Coadministration of halofantrine with other drugs that can prolong the QT interval is considered contraindicated.', NULL, 'Coadministration of halofantrine with other drugs that can prolong the QT interval is considered contraindicated.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1510976, 'Idarubicin', 'Halothane', 'Moderate', 'Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.', NULL, 'Caution and clinical monitoring are recommended.', NULL, 'Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1510977, 'Idelalisib', 'Idarubicin', 'Moderate', 'The risk and/or severity of diarrhea may be increased when idelalisib is used with other agents that cause diarrhea.', NULL, 'Concomitant use of idelalisib with other drugs that cause diarrhea should be avoided whenever possible.', NULL, 'Concomitant use of idelalisib with other drugs that cause diarrhea should be avoided whenever possible. Patients treated with idelalisib should be monitored for development of severe diarrhea or colitis during treatment in accordance with the product labeling, and the dosing adjusted or interrupted as necessary. Permanent discontinuation of idelalisib is recommended in those who experience life-threatening diarrhea or intestinal perforation.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1510978, 'Ifosfamide', 'Idarubicin', 'Moderate', 'The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.', NULL, 'Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.', NULL, 'Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers'' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1510979, 'Iloperidone', 'Idarubicin', 'Major', 'Iloperidone may cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'Coadministration of iloperidone with other drugs that can prolong the QT interval should generally be avoided.', NULL, 'Coadministration of iloperidone with other drugs that can prolong the QT interval should generally be avoided. Caution and clinical monitoring are recommended if concomitant use is required. Patients should have regular ECGs and be monitored for arrhythmias when QT interval is prolonged. Persistent QTc measurements exceeding 500 msec will require suspension of iloperidone therapy and immediate action to correct any concomitant risk factors before resuming treatment.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1510980, 'Imatinib', 'Idarubicin', 'Moderate', 'The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.', NULL, 'Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.', NULL, 'Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers'' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1510981, 'Imipramine', 'Idarubicin', 'Moderate', 'Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.', NULL, 'Caution and clinical monitoring are recommended.', NULL, 'Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1510982, 'Indacaterol', 'Idarubicin', 'Moderate', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1510983, 'Infliximab', 'Idarubicin', 'Major', 'The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Serious infections and sepsis, including fatalities, have been reported with the use of TNF blockers, particularly in patients on concomitant immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids. Concomitant use of TNF blockers with other immunosuppressants such as azathioprine or mercaptopurine may also increase the risk of a rare and often fatal cancer of white blood cells known as hepatosplenic T-Cell lymphoma (HSTCL).', NULL, 'Patients receiving a TNF blocker alone or with other immunosuppressive or myelosuppressive agents should be monitored closely for the development of infections.', NULL, 'Patients receiving a TNF blocker alone or with other immunosuppressive or myelosuppressive agents should be monitored closely for the development of infections. TNF blocker therapy should be discontinued if a serious infection or sepsis occurs. Close monitoring for signs and symptoms of HSTCL (e.g., splenomegaly, hepatomegaly, abdominal pain, persistent fever, night sweats, weight loss) is also recommended during use of TNF blockers, particularly in combination with other immunosuppressants such as azathioprine and mercaptopurine.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1510984, 'Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)', 'Idarubicin', 'Moderate', 'The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.', NULL, 'In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.', NULL, 'In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin''s disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.', 'Antagonism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1510985, 'Influenza A virus A/Vietnam/1194/2004 (H5N1) antigen (formaldehyde inactivated)', 'Idarubicin', 'Moderate', 'The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.', NULL, 'In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.', NULL, 'In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin''s disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.', 'Antagonism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1510986, 'Interferon alfa-2a, Recombinant', 'Idarubicin', 'Moderate', 'The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.', NULL, 'Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.', NULL, 'Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers'' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1510987, 'Isoetharine', 'Idarubicin', 'Moderate', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1510988, 'Idarubicin', 'Lactobacillus acidophilus', 'Moderate', 'Probiotic use during immunosuppressant or intense antineoplastic therapy may theoretically increase the risk of infections from the live microorganisms contained in probiotic products. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.', NULL, 'Caution is advised when probiotics are used during immunosuppressant or intense antineoplastic therapy.', NULL, 'Caution is advised when probiotics are used during immunosuppressant or intense antineoplastic therapy. It may be advisable to avoid using probiotics, particularly products containing saccharomyces boulardii, in patients who are significantly immunosuppressed.', 'Others', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1510989, 'Idarubicin', 'Levacetylmethadol', 'Major', 'Levomethadyl acetate may cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. High dosages of levomethadyl acetate alone have been associated with QT interval prolongation and torsade de pointes.', NULL, 'Coadministration of levomethadyl acetate with other drugs that can prolong the QT interval is considered contraindicated.', NULL, 'Coadministration of levomethadyl acetate with other drugs that can prolong the QT interval is considered contraindicated.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1510990, 'Idarubicin', 'Lomefloxacin', 'Minor', 'Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics. The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.', NULL, '-', NULL, '-', 'Absorption', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1510991, 'Idarubicin', 'Lomitapide', 'Moderate', 'Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of daunorubicin and idarubicin, both of which are substrates of the efflux transporter also known as ABCB1 or MDR1. The interaction has been studied with cyclosporine, a potent P-gp inhibitor, in attempt to overcome multidrug resistance in MDR1-overexpressing tumors.', NULL, 'Caution is advised if daunorubicin or idarubicin is prescribed in combination with a P-gp inhibitor.', NULL, 'Caution is advised if daunorubicin or idarubicin is prescribed in combination with a P-gp inhibitor. Patients should be closely monitored for increased adverse effects including cardiotoxicity and myelosuppression.', 'Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1510992, 'Idarubicin', 'Lyme disease vaccine (recombinant OspA)', 'Moderate', 'The administration of Lyme disease vaccine to immunosuppressed patients may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.', NULL, 'The manufacturer suggests considering deferral of vaccination against Lyme disease until 3 months after discontinuation of immunosuppressive therapy.', NULL, 'The manufacturer suggests considering deferral of vaccination against Lyme disease until 3 months after discontinuation of immunosuppressive therapy. Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison''s disease).', 'Others', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1510993, 'Idarubicin', 'Mesoridazine', 'Major', 'Mesoridazine can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Mesoridazine overdosage has been associated with ventricular arrhythmias and death. The extent of drug-induced QT prolongation is dependent on the particular drug(s) involved and dosage(s) of the drug(s). In addition, certain agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive parasympatholytic and central nervous system-depressant effects when used in combination with mesoridazine. Excessive parasympatholytic effects may include paralytic ileus, hyperthermia, mydriasis, blurred vision, tachycardia, urinary retention, psychosis, and seizures.', NULL, 'Coadministration of mesoridazine with other drugs that can prolong the QT interval is considered contraindicated.', NULL, 'Coadministration of mesoridazine with other drugs that can prolong the QT interval is considered contraindicated.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1510994, 'Idarubicin', 'Methotrimeprazine', 'Moderate', 'Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.', NULL, 'Caution and clinical monitoring are recommended.', NULL, 'Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1510995, 'Idarubicin', 'Mumps virus strain B level jeryl lynn live antigen', 'Major', 'The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids. These patients may also have increased adverse reactions and decreased or suboptimal immunologic response to vaccines.', NULL, 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.', NULL, 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide). Current local immunization guidelines should be consulted for recommendations.', 'Others', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1510996, 'Idarubicin', 'Nalidixic acid', 'Minor', 'Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics. The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.', NULL, '-', NULL, '-', 'Absorption', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1510997, 'Idarubicin', 'Naxitamab', 'Moderate', 'The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.', NULL, 'Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.', NULL, 'Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers'' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1510998, 'Idarubicin', 'Papaverine', 'Major', 'Intracoronary administration of papaverine has been associated with QT interval prolongation and torsade de pointes (TdP) arrhythmia. The risk may theoretically increase in patients receiving concomitant medications that can also prolong the QT interval or cause bradycardia. The precise mechanism of papaverine-induced ventricular tachyarrhythmias has not been delineated, but may involve inhibition of potassium currents and prolongation of the action potential duration.', NULL, 'Caution and close monitoring are advised during intracoronary administration of papaverine, particularly in patients receiving concomitant drugs that can prolong the QT interval or cause bradycardia and in patients with other risk factors described above.', NULL, 'Caution and close monitoring are advised during intracoronary administration of papaverine, particularly in patients receiving concomitant drugs that can prolong the QT interval or cause bradycardia and in patients with other risk factors described above.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1510999, 'Idarubicin', 'Perphenazine', 'Moderate', 'Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.', NULL, 'Caution and clinical monitoring are recommended.', NULL, 'Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511000, 'Idarubicin', 'Primaquine', 'Moderate', 'Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.', NULL, 'Caution and clinical monitoring are recommended.', NULL, 'Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511001, 'Idarubicin', 'Probucol', 'Moderate', 'Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.', NULL, 'Caution and clinical monitoring are recommended.', NULL, 'Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511002, 'Idarubicin', 'Promazine', 'Moderate', 'Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.', NULL, 'Caution and clinical monitoring are recommended.', NULL, 'Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511003, 'Idarubicin', 'Quinidine', 'Major', 'Class IA (e.g., disopyramide, quinidine, procainamide) and class III (e.g., amiodarone, dofetilide, sotalol) antiarrhythmic agents can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'Coadministration of class IA or class III antiarrhythmic agents with other drugs that can prolong the QT interval should preferably be avoided unless benefits are anticipated to outweigh the risks.', NULL, 'Coadministration of class IA or class III antiarrhythmic agents with other drugs that can prolong the QT interval should preferably be avoided unless benefits are anticipated to outweigh the risks. Caution and clinical monitoring are recommended if concomitant use is required. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511004, 'Idarubicin', 'Radium Ra 223 dichloride', 'Moderate', 'The concomitant use of bone marrow depressants and radium Ra 223 dichloride may have additive myelosuppressive effects.', NULL, 'Patients should be monitored for excessive bone marrow suppression during treatment with radium Ra 223 dichloride.', NULL, 'Patients should be monitored for excessive bone marrow suppression during treatment with radium Ra 223 dichloride. Dose reductions of the other bone marrow depressants may be necessary. Patients should be advised to contact their physician if they develop signs and symptoms of myelosuppression such as pallor, dizziness, fatigue, lethargy, fainting, easy bruising or bleeding, or signs of infection such as fever, chills, sore throat, body aches, and other influenza-like symptoms. The safety and efficacy of concomitant use of chemotherapy have not been established.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511005, 'Idarubicin', 'Relugolix', 'Moderate', 'Long-term androgen deprivation therapy can prolong the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, the extent of drug-induced QT prolongation is dependent on the particular drug(s) involved and dosage(s) of the drug(s).', NULL, 'The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.', NULL, 'The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval. Electrolyte abnormalities should be corrected prior to initiating therapy, and periodic monitoring of electrocardiograms and electrolytes should be considered.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511006, 'Idarubicin', 'Ritodrine', 'Moderate', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511007, 'Idarubicin', 'Rubella virus vaccine', 'Major', 'The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids. These patients may also have increased adverse reactions and decreased or suboptimal immunologic response to vaccines.', NULL, 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.', NULL, 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide). Current local immunization guidelines should be consulted for recommendations.', 'Others', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511008, 'Idarubicin', 'Pfizer-BioNTech Covid-19 Vaccine', 'Moderate', 'The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.', NULL, 'In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.', NULL, 'In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin''s disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.', 'Antagonism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511009, 'Idarubicin', 'Smallpox (Vaccinia) Vaccine, Live', 'Major', 'The administration of live smallpox virus vaccine during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.', NULL, 'Routine, nonemergency smallpox vaccination is contraindicated in patients receiving immunosuppressive therapy or cancer chemotherapy.', NULL, 'Routine, nonemergency smallpox vaccination is contraindicated in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued for at least 3 months in most cases. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide).', 'Others', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511010, 'Idarubicin', 'Sodium phosphate, monobasic (p32)', 'Moderate', 'The concomitant use of bone marrow depressants and sodium phosphate P-32 may have additive myelosuppressive effects.', NULL, 'Patients should be monitored for excessive bone marrow suppression during treatment with sodium phosphate P-32.', NULL, 'Patients should be monitored for excessive bone marrow suppression during treatment with sodium phosphate P-32. Dose reductions of the other bone marrow depressants may be necessary. Patients should be advised to contact their physician if they develop signs and symptoms of myelosuppression such as pallor, dizziness, fatigue, lethargy, fainting, easy bruising or bleeding, or signs of infection such as fever, chills, sore throat, body aches, and other influenza-like symptoms.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511011, 'Idarubicin', 'Sparfloxacin', 'Major', 'Sparfloxacin may cause dose-related prolongation of the QT interval in some patients. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'Coadministration of sparfloxacin with other drugs that can prolong the QT interval is considered contraindicated.', NULL, 'Coadministration of sparfloxacin with other drugs that can prolong the QT interval is considered contraindicated.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511012, 'Idarubicin', 'Tacrine', 'Moderate', 'Acetylcholinesterase inhibitors may have vagotonic effects on the sinoatrial and atrioventricular nodes, which occasionally manifest as bradycardia or heart block (<2%). Because bradycardia is a risk factor for torsade de pointes, a theoretical risk exists when combined with agents that prolong the QT interval.', NULL, 'Caution is advised when acetylcholinesterase inhibitors are used with drugs that can prolong the QT interval.', NULL, 'Caution is advised when acetylcholinesterase inhibitors are used with drugs that can prolong the QT interval. Patients should be monitored for bradycardia, atrioventricular block and syncope, and advised to seek medical attention if they experience dizziness, lightheadedness, fainting, shortness of breath, or slow or irregular heartbeat.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511013, 'Idarubicin', 'Telaprevir', 'Moderate', 'Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of daunorubicin and idarubicin, both of which are substrates of the efflux transporter also known as ABCB1 or MDR1. The interaction has been studied with cyclosporine, a potent P-gp inhibitor, in attempt to overcome multidrug resistance in MDR1-overexpressing tumors.', NULL, 'Caution is advised if daunorubicin or idarubicin is prescribed in combination with a P-gp inhibitor.', NULL, 'Caution is advised if daunorubicin or idarubicin is prescribed in combination with a P-gp inhibitor. Patients should be closely monitored for increased adverse effects including cardiotoxicity and myelosuppression.', 'Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511014, 'Idarubicin', 'Terbutaline', 'Moderate', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511015, 'Idarubicin', 'Terfenadine', 'Moderate', 'Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.', NULL, 'Caution and clinical monitoring are recommended.', NULL, 'Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511016, 'Idarubicin', 'Thioridazine', 'Major', 'Thioridazine can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, certain agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive parasympatholytic and central nervous system-depressant effects when used in combination with thioridazine. Excessive parasympatholytic effects may include paralytic ileus, hyperthermia, mydriasis, blurred vision, tachycardia, urinary retention, psychosis, and seizures.', NULL, 'Coadministration of thioridazine with other drugs that can prolong the QT interval is considered contraindicated.', NULL, 'Coadministration of thioridazine with other drugs that can prolong the QT interval is considered contraindicated.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511017, 'Idarubicin', 'Trichophyton mentagrophytes', 'Moderate', 'Immunosuppressed patients may have diminished response to diagnostic skin test antigens due to suppression of cell-mediated, delayed-type hypersensitivity. Falsely insignificant or false-negative results may occur in such patients, which may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.', NULL, 'Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.', NULL, 'Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.', 'Others', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511018, 'Idarubicin', 'Trifluoperazine', 'Moderate', 'Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.', NULL, 'Caution and clinical monitoring are recommended.', NULL, 'Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511019, 'Idarubicin', 'Triflupromazine', 'Moderate', 'Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.', NULL, 'Caution and clinical monitoring are recommended.', NULL, 'Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511020, 'Idarubicin', 'Alimemazine', 'Moderate', 'Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.', NULL, 'Caution and clinical monitoring are recommended.', NULL, 'Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511021, 'Idarubicin', 'Trovafloxacin', 'Minor', 'Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics. The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.', NULL, '-', NULL, '-', 'Absorption', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511022, 'Idarubicin', 'Typhoid vaccine (inactivated)', 'Moderate', 'The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.', NULL, 'In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.', NULL, 'In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin''s disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.', 'Antagonism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511023, 'Idarubicin', 'Typhoid vaccine (live)', 'Major', 'The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids. These patients may also have increased adverse reactions and decreased or suboptimal immunologic response to vaccines.', NULL, 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.', NULL, 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide). Current local immunization guidelines should be consulted for recommendations.', 'Others', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511024, 'Idarubicin', 'Vinblastine', 'Moderate', 'The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.', NULL, 'Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.', NULL, 'Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers'' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511025, 'Idarubicin', 'Vitamin E', 'Moderate', 'The potential effects of vitamin E on cancer chemotherapy and radiation have not been established. Because vitamin E is an antioxidant, pharmacologic doses could theoretically interfere with radiation therapy and chemotherapeutic agents whose cytotoxic mechanism depends on generation of reactive oxygen species (ROS) that damage DNA and proteins, including but not limited to alkylating agents (e.g., busulfan, cyclophosphamide, melphalan), anthracyclines (e.g., doxorubicin, epirubicin), platinum coordination complexes (e.g., cisplatin, carboplatin), DNA topoisomerase inhibitors (e.g., etoposide, teniposide, irinotecan, topotecan), and photodynamic agents (e.g., porfimer). On the other hand, vitamin E may help reduce oxidative stress associated with more aggressive cancers and protect non-cancer cells from oxidative damage generated by cancer treatments, which can enhance patient tolerance and lessen the need for reducing dosage or duration of treatment.', NULL, 'Until more information is available, vitamin E supplementation should preferably be avoided in patients undergoing cancer chemotherapy or radiation treatment.', NULL, 'Until more information is available, vitamin E supplementation should preferably be avoided in patients undergoing cancer chemotherapy or radiation treatment. Clinicians should closely monitor antitumor response if vitamin E is used in these patients. No specific dosing of vitamin E has been established for uses other than to treat vitamin E deficiency. There has been evidence suggesting possible adverse health effects including increased risk of heart failure and mortality in association with long-term use of 400 IU/day or greater.', 'Others', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511026, 'Idelalisib', 'Abarelix', 'Moderate', 'The risk and/or severity of diarrhea may be increased when idelalisib is used with other agents that cause diarrhea.', NULL, 'Concomitant use of idelalisib with other drugs that cause diarrhea should be avoided whenever possible.', NULL, 'Concomitant use of idelalisib with other drugs that cause diarrhea should be avoided whenever possible. Patients treated with idelalisib should be monitored for development of severe diarrhea or colitis during treatment in accordance with the product labeling, and the dosing adjusted or interrupted as necessary. Permanent discontinuation of idelalisib is recommended in those who experience life-threatening diarrhea or intestinal perforation.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511027, 'Idelalisib', 'Human adenovirus e serotype 4 strain cl-68578 antigen', 'Moderate', 'There are no data regarding the use of live, unattenuated Adenovirus Type 4 and Type 7 vaccine during treatment with immunosuppressive therapies, including alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids. It is not known whether immunosuppressed patients may have an increased risk of adverse reactions or a decreased or suboptimal immunologic response to the vaccine.', NULL, 'The safety and efficacy of live, unattenuated Adenovirus Type 4 and Type 7 vaccine have not been established in patients receiving immunosuppressive therapies.', NULL, 'The safety and efficacy of live, unattenuated Adenovirus Type 4 and Type 7 vaccine have not been established in patients receiving immunosuppressive therapies. Caution is advised.', 'Others', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511028, 'Idelalisib', 'Aminoglutethimide', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of idelalisib, which is a substrate of the isoenzyme.', NULL, 'Patients receiving idelalisib with CYP450 3A4 inducers should be monitored for potentially diminished pharmacologic response to idelalisib.', NULL, 'Patients receiving idelalisib with CYP450 3A4 inducers should be monitored for potentially diminished pharmacologic response to idelalisib. Concomitant use should be avoided if an interaction is suspected.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511029, 'Idelalisib', 'Amprenavir', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 and/or P-glycoprotein (P-gp) may increase the plasma concentrations of idelalisib, which is a substrate of both the isoenzyme and efflux transporter.', NULL, 'Caution is advised if idelalisib is prescribed in combination with CYP450 3A4 and/or P-gp inhibitors.', NULL, 'Caution is advised if idelalisib is prescribed in combination with CYP450 3A4 and/or P-gp inhibitors. Pharmacologic response to idelalisib should be monitored more closely whenever a CYP450 3A4/P-gp inhibitor is added to or withdrawn from therapy, and the idelalisib dosing adjusted or interrupted as necessary in accordance with the product labeling. Patients should be closely monitored for idelalisib toxicity such as hepatotoxicity, diarrhea, colitis, intestinal perforation, pneumonitis, neutropenia, and thrombocytopenia.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511030, 'Idelalisib', 'Astemizole', 'Moderate', 'Coadministration with idelalisib may increase the plasma concentrations of drugs that are substrates of CYP450 3A4. Idelalisib has been shown to be a potent inhibitor of this isoenzyme.', NULL, 'Use of idelalisib should generally be avoided with drugs that are primarily metabolized by CYP450 3A4, particularly those with a narrow therapeutic range (e.', NULL, 'Use of idelalisib should generally be avoided with drugs that are primarily metabolized by CYP450 3A4, particularly those with a narrow therapeutic range (e.g., antiarrhythmics, anticonvulsants, antineoplastics, immunosuppressants) or those that are considered sensitive substrates (e.g., ergot derivatives, statins, oral midazolam, triazolam). Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever idelalisib is added to or withdrawn from therapy, if coadministration is required.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511031, 'Idelalisib', 'Bacillus calmette-guerin substrain tice live antigen', 'Major', 'The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids. These patients may also have increased adverse reactions and decreased or suboptimal immunologic response to vaccines.', NULL, 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.', NULL, 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide). Current local immunization guidelines should be consulted for recommendations.', 'Others', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511032, 'Idelalisib', 'Bedaquiline', 'Moderate', 'Coadministration of idelalisib with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. The use of idelalisib has been associated with elevations in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) greater than 5 times the upper limit of normal.', NULL, 'The use of idelalisib with other potentially hepatotoxic agents should be avoided whenever possible (e.', NULL, 'The use of idelalisib with other potentially hepatotoxic agents should be avoided whenever possible (e.g., acetaminophen; alcohol; amiodarone; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; methotrexate; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; tetracyclines; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients treated with idelalisib should have serum ALT, AST, and bilirubin measured prior to initiation of treatment and regularly during treatment in accordance with the product labeling, and the dosing adjusted or interrupted as necessary.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511033, 'Idelalisib', 'Belinostat', 'Moderate', 'Coadministration of idelalisib with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. The use of idelalisib has been associated with elevations in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) greater than 5 times the upper limit of normal. The risk and/or severity of diarrhea may be increased when idelalisib is used with other agents that cause diarrhea.', NULL, 'The use of idelalisib with other agents that can induce hepatotoxicity and/or diarrhea should be avoided whenever possible.', NULL, 'The use of idelalisib with other agents that can induce hepatotoxicity and/or diarrhea should be avoided whenever possible. Patients treated with idelalisib should be monitored for development of severe diarrhea or colitis and have serum ALT, AST, and bilirubin measured prior to initiation of treatment and regularly during treatment in accordance with the product labeling, and the dosing adjusted or interrupted as necessary. Permanent discontinuation of idelalisib is recommended in those who experience recurrent hepatotoxicity following dosage reduction and/or life-threatening diarrhea or intestinal perforation. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Patients should also contact their physician immediately if the number of bowel movements per day increases by six or more, or if they have new or worsening abdominal pain, chills, fever, nausea, or vomiting.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511034, 'Idelalisib', 'Bepridil', 'Moderate', 'Coadministration with idelalisib may increase the plasma concentrations of drugs that are substrates of CYP450 3A4. Idelalisib has been shown to be a potent inhibitor of this isoenzyme.', NULL, 'Use of idelalisib should generally be avoided with drugs that are primarily metabolized by CYP450 3A4, particularly those with a narrow therapeutic range (e.', NULL, 'Use of idelalisib should generally be avoided with drugs that are primarily metabolized by CYP450 3A4, particularly those with a narrow therapeutic range (e.g., antiarrhythmics, anticonvulsants, antineoplastics, immunosuppressants) or those that are considered sensitive substrates (e.g., ergot derivatives, statins, oral midazolam, triazolam). Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever idelalisib is added to or withdrawn from therapy, if coadministration is required.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511035, 'Idelalisib', 'Berotralstat', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 and/or P-glycoprotein (P-gp) may increase the plasma concentrations of idelalisib, which is a substrate of both the isoenzyme and efflux transporter.', NULL, 'Caution is advised if idelalisib is prescribed in combination with CYP450 3A4 and/or P-gp inhibitors.', NULL, 'Caution is advised if idelalisib is prescribed in combination with CYP450 3A4 and/or P-gp inhibitors. Pharmacologic response to idelalisib should be monitored more closely whenever a CYP450 3A4/P-gp inhibitor is added to or withdrawn from therapy, and the idelalisib dosing adjusted or interrupted as necessary in accordance with the product labeling. Patients should be closely monitored for idelalisib toxicity such as hepatotoxicity, diarrhea, colitis, intestinal perforation, pneumonitis, neutropenia, and thrombocytopenia.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511036, 'Idelalisib', 'Bifidobacterium longum infantis', 'Moderate', 'Probiotic use during immunosuppressant or intense antineoplastic therapy may theoretically increase the risk of infections from the live microorganisms contained in probiotic products. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.', NULL, 'Caution is advised when probiotics are used during immunosuppressant or intense antineoplastic therapy.', NULL, 'Caution is advised when probiotics are used during immunosuppressant or intense antineoplastic therapy. It may be advisable to avoid using probiotics, particularly products containing saccharomyces boulardii, in patients who are significantly immunosuppressed.', 'Others', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511037, 'Idelalisib', 'Boceprevir', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 and/or P-glycoprotein (P-gp) may increase the plasma concentrations of idelalisib, which is a substrate of both the isoenzyme and efflux transporter.', NULL, 'Caution is advised if idelalisib is prescribed in combination with CYP450 3A4 and/or P-gp inhibitors.', NULL, 'Caution is advised if idelalisib is prescribed in combination with CYP450 3A4 and/or P-gp inhibitors. Pharmacologic response to idelalisib should be monitored more closely whenever a CYP450 3A4/P-gp inhibitor is added to or withdrawn from therapy, and the idelalisib dosing adjusted or interrupted as necessary in accordance with the product labeling. Patients should be closely monitored for idelalisib toxicity such as hepatotoxicity, diarrhea, colitis, intestinal perforation, pneumonitis, neutropenia, and thrombocytopenia.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511038, 'Idelalisib', 'Bromfenac', 'Moderate', 'Coadministration of idelalisib with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. The use of idelalisib has been associated with elevations in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) greater than 5 times the upper limit of normal.', NULL, 'The use of idelalisib with other potentially hepatotoxic agents should be avoided whenever possible (e.', NULL, 'The use of idelalisib with other potentially hepatotoxic agents should be avoided whenever possible (e.g., acetaminophen; alcohol; amiodarone; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; methotrexate; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; tetracyclines; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients treated with idelalisib should have serum ALT, AST, and bilirubin measured prior to initiation of treatment and regularly during treatment in accordance with the product labeling, and the dosing adjusted or interrupted as necessary.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511039, 'Idelalisib', 'Butabarbital', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of idelalisib, which is a substrate of the isoenzyme.', NULL, 'Patients receiving idelalisib with CYP450 3A4 inducers should be monitored for potentially diminished pharmacologic response to idelalisib.', NULL, 'Patients receiving idelalisib with CYP450 3A4 inducers should be monitored for potentially diminished pharmacologic response to idelalisib. Concomitant use should be avoided if an interaction is suspected.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511040, 'Idelalisib', 'Candida albicans', 'Moderate', 'Immunosuppressed patients may have diminished response to diagnostic skin test antigens due to suppression of cell-mediated, delayed-type hypersensitivity. Falsely insignificant or false-negative results may occur in such patients, which may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.', NULL, 'Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.', NULL, 'Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.', 'Others', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511041, 'Idelalisib', 'Caspofungin', 'Moderate', 'Coadministration of idelalisib with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. The use of idelalisib has been associated with elevations in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) greater than 5 times the upper limit of normal.', NULL, 'The use of idelalisib with other potentially hepatotoxic agents should be avoided whenever possible (e.', NULL, 'The use of idelalisib with other potentially hepatotoxic agents should be avoided whenever possible (e.g., acetaminophen; alcohol; amiodarone; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; methotrexate; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; tetracyclines; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients treated with idelalisib should have serum ALT, AST, and bilirubin measured prior to initiation of treatment and regularly during treatment in accordance with the product labeling, and the dosing adjusted or interrupted as necessary.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511042, 'Idelalisib', 'Cerivastatin', 'Moderate', 'Coadministration with idelalisib may increase the plasma concentrations of drugs that are substrates of CYP450 3A4. Idelalisib has been shown to be a potent inhibitor of this isoenzyme.', NULL, 'Use of idelalisib should generally be avoided with drugs that are primarily metabolized by CYP450 3A4, particularly those with a narrow therapeutic range (e.', NULL, 'Use of idelalisib should generally be avoided with drugs that are primarily metabolized by CYP450 3A4, particularly those with a narrow therapeutic range (e.g., antiarrhythmics, anticonvulsants, antineoplastics, immunosuppressants) or those that are considered sensitive substrates (e.g., ergot derivatives, statins, oral midazolam, triazolam). Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever idelalisib is added to or withdrawn from therapy, if coadministration is required.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511043, 'Idelalisib', 'Vibrio cholerae CVD 103-HgR strain live antigen', 'Moderate', 'The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.', NULL, 'In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.', NULL, 'In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin''s disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.', 'Antagonism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511044, 'Idelalisib', 'Cisapride', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of cisapride, which is primarily metabolized by the isoenzyme. High plasma levels of cisapride have been associated with prolongation of the QT interval on the ECG; ventricular arrhythmias including ventricular tachycardia, ventricular fibrillation, and torsade de pointes; cardiac arrest; and sudden death.', NULL, 'Given the potential for serious and life-threatening adverse cardiac events associated with increased plasma levels of cisapride, the concomitant use of cisapride with potent CYP450 3A4 inhibitors is considered contraindicated.', NULL, 'Given the potential for serious and life-threatening adverse cardiac events associated with increased plasma levels of cisapride, the concomitant use of cisapride with potent CYP450 3A4 inhibitors is considered contraindicated.', 'Metabolism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511045, 'Idelalisib', 'Clotrimazole', 'Moderate', 'Coadministration of idelalisib with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. The use of idelalisib has been associated with elevations in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) greater than 5 times the upper limit of normal. Coadministration with inhibitors of CYP450 3A4 and/or P-glycoprotein (P-gp) may increase the plasma concentrations of idelalisib, which is a substrate of both the isoenzyme and efflux transporter.', NULL, 'The use of idelalisib with other potentially hepatotoxic agents such as azole antifungal agents, macrolide antibiotics, nefazodone, ritonavir, and telithromycin should be avoided whenever possible.', NULL, 'The use of idelalisib with other potentially hepatotoxic agents such as azole antifungal agents, macrolide antibiotics, nefazodone, ritonavir, and telithromycin should be avoided whenever possible. In addition, these agents are potent CYP450 3A4/P-gp inhibitors and may increase the toxicity of idelalisib. Caution is advised if coadministration is required. Patients should be closely monitored for hepatotoxicity and other toxicities of idelalisib such as diarrhea, colitis, intestinal perforation, pneumonitis, neutropenia and thrombocytopenia, and the dosing adjusted or interrupted as necessary. Patients should have serum ALT, AST, and bilirubin measured prior to initiation of treatment and regularly during treatment in accordance with the product labeling. Permanent discontinuation of idelalisib is recommended in those who experience recurrent hepatotoxicity following dosage reduction. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.', 'Metabolism, Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511046, 'Idelalisib', 'Coccidioides immitis spherule', 'Moderate', 'Immunosuppressed patients may have diminished response to diagnostic skin test antigens due to suppression of cell-mediated, delayed-type hypersensitivity. Falsely insignificant or false-negative results may occur in such patients, which may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.', NULL, 'Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.', NULL, 'Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.', 'Others', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511047, 'Idelalisib', 'Copanlisib', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 and P-glycoprotein (P-gp) may increase the plasma concentrations of copanlisib, which is a substrate of both the isoenzyme and efflux transporter.', NULL, 'The manufacturer recommends reducing the copanlisib dose to 45 mg when concomitant use with potent CYP450 3A4 inhibitors cannot be avoided.', NULL, 'The manufacturer recommends reducing the copanlisib dose to 45 mg when concomitant use with potent CYP450 3A4 inhibitors cannot be avoided.', 'Metabolism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511048, 'Idelalisib', 'Cytarabine', 'Moderate', 'Coadministration of idelalisib with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. The use of idelalisib has been associated with elevations in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) greater than 5 times the upper limit of normal. The risk and/or severity of diarrhea may be increased when idelalisib is used with other agents that cause diarrhea.', NULL, 'The use of idelalisib with other agents that can induce hepatotoxicity and/or diarrhea should be avoided whenever possible.', NULL, 'The use of idelalisib with other agents that can induce hepatotoxicity and/or diarrhea should be avoided whenever possible. Patients treated with idelalisib should be monitored for development of severe diarrhea or colitis and have serum ALT, AST, and bilirubin measured prior to initiation of treatment and regularly during treatment in accordance with the product labeling, and the dosing adjusted or interrupted as necessary. Permanent discontinuation of idelalisib is recommended in those who experience recurrent hepatotoxicity following dosage reduction and/or life-threatening diarrhea or intestinal perforation. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Patients should also contact their physician immediately if the number of bowel movements per day increases by six or more, or if they have new or worsening abdominal pain, chills, fever, nausea, or vomiting.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511049, 'Idelalisib', 'Cytarabine (liposomal)', 'Moderate', 'The risk and/or severity of diarrhea may be increased when idelalisib is used with other agents that cause diarrhea.', NULL, 'Concomitant use of idelalisib with other drugs that cause diarrhea should be avoided whenever possible.', NULL, 'Concomitant use of idelalisib with other drugs that cause diarrhea should be avoided whenever possible. Patients treated with idelalisib should be monitored for development of severe diarrhea or colitis during treatment in accordance with the product labeling, and the dosing adjusted or interrupted as necessary. Permanent discontinuation of idelalisib is recommended in those who experience life-threatening diarrhea or intestinal perforation.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511050, 'Idelalisib', 'Dacarbazine', 'Moderate', 'Coadministration of idelalisib with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. The use of idelalisib has been associated with elevations in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) greater than 5 times the upper limit of normal.', NULL, 'The use of idelalisib with other potentially hepatotoxic agents should be avoided whenever possible (e.', NULL, 'The use of idelalisib with other potentially hepatotoxic agents should be avoided whenever possible (e.g., acetaminophen; alcohol; amiodarone; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; methotrexate; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; tetracyclines; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients treated with idelalisib should have serum ALT, AST, and bilirubin measured prior to initiation of treatment and regularly during treatment in accordance with the product labeling, and the dosing adjusted or interrupted as necessary.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511051, 'Idelalisib', 'Demeclocycline', 'Moderate', 'Coadministration of idelalisib with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. The use of idelalisib has been associated with elevations in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) greater than 5 times the upper limit of normal.', NULL, 'The use of idelalisib with other potentially hepatotoxic agents should be avoided whenever possible (e.', NULL, 'The use of idelalisib with other potentially hepatotoxic agents should be avoided whenever possible (e.g., acetaminophen; alcohol; amiodarone; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; methotrexate; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; tetracyclines; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients treated with idelalisib should have serum ALT, AST, and bilirubin measured prior to initiation of treatment and regularly during treatment in accordance with the product labeling, and the dosing adjusted or interrupted as necessary.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511052, 'Idelalisib', 'Dexamethasone (nasal)', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations and pharmacologic effects of corticosteroids, which are primarily metabolized by the isoenzyme. The interaction has been reported with potent inhibitors such as clarithromycin, erythromycin, itraconazole, nefazodone, cobicistat, and ritonavir during concomitant use of various corticosteroids, including inhaled, nasal, and ophthalmic formulations. Systemic corticosteroid adverse effects may occur following intensive or long-term continuous ophthalmic corticosteroid therapy. Cushing''s syndrome and adrenal insufficiency have been attributed to the interaction.', NULL, 'The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors.', NULL, 'The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors. When indicated for intranasal or inhalational use, alternative corticosteroids such as beclomethasone, which is less dependent on CYP450 3A4 metabolism, should be considered, particularly if long term treatment is required. Patients should be monitored for signs and symptoms of hypercorticism such as acne, striae, thinning of the skin, easy bruising, moon facies, dorsocervical "buffalo" hump, truncal obesity, increased appetite, acute weight gain, edema, hypertension, hirsutism, hyperhidrosis, proximal muscle wasting and weakness, glucose intolerance, exacerbation of preexisting diabetes, depression, and menstrual disorders. Other systemic glucocorticoid effects may include adrenal suppression, immunosuppression, posterior subcapsular cataracts, glaucoma, bone loss, and growth retardation in children and adolescents. Following extensive use with a potent CYP450 3A4 inhibitor, a progressive dosage reduction may be required over a longer period if the corticosteroid is to be withdrawn from therapy, as there may be a significant risk of adrenal suppression.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511053, 'Idelalisib', 'Doxorubicin (liposomal)', 'Moderate', 'Coadministration with idelalisib may increase the plasma concentrations of drugs that are substrates of CYP450 3A4. Idelalisib has been shown to be a potent inhibitor of this isoenzyme.', NULL, 'Use of idelalisib should generally be avoided with drugs that are primarily metabolized by CYP450 3A4, particularly those with a narrow therapeutic range (e.', NULL, 'Use of idelalisib should generally be avoided with drugs that are primarily metabolized by CYP450 3A4, particularly those with a narrow therapeutic range (e.g., antiarrhythmics, anticonvulsants, antineoplastics, immunosuppressants) or those that are considered sensitive substrates (e.g., ergot derivatives, statins, oral midazolam, triazolam). Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever idelalisib is added to or withdrawn from therapy, if coadministration is required.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511054, 'Idelalisib', 'Echinacea', 'Moderate', 'Coadministration with echinacea may alter the plasma concentrations and therapeutic effects of drugs that are substrates of CYP450 3A4. Echinacea appears to inhibit intestinal CYP450 3A4, which would lead to an increase in oral midazolam (a sensitive 3A4 substrate) bioavailability; however, plasma levels of midazolam following oral administration do not appear to be affected by echinacea. In contrast, it appears that echinacea may also induce hepatic CYP450 3A4; thereby increasing the hepatic clearance of drugs that are substrates of CYP450 3A4.', NULL, 'In general, patients should be advised to consult their healthcare provider before using any herbal or alternative medicines.', NULL, 'In general, patients should be advised to consult their healthcare provider before using any herbal or alternative medicines. If echinacea is prescribed with a drug that is a CYP450 3A4 substrate, the possibility of an altered (increased or decreased) therapeutic response should be considered. Patients should be monitored more closely following the addition or withdrawal of echinacea and the dosage of the CYP450 3A4 substrate adjusted as necessary.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511055, 'Idelalisib', 'Efalizumab', 'Moderate', 'The use of efalizumab with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Efalizumab alone can cause serious infections requiring hospitalization, and the risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'The safety and efficacy of efalizumab in combination with other immunosuppressive agents or phototherapy have not been evaluated.', NULL, 'The safety and efficacy of efalizumab in combination with other immunosuppressive agents or phototherapy have not been evaluated. Patients receiving other immunosuppressive agents should not be treated with efalizumab because of the possibility of excessive immunosuppression. The duration of the period following treatment with efalizumab before one should consider starting other immunosuppressive therapy has not been evaluated.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511056, 'Idelalisib', 'Ergometrine', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of ergot derivatives, which are primarily metabolized by the isoenzyme. The interaction has occurred in patients receiving ergotamine or dihydroergotamine with potent CYP450 3A4 inhibitors such as macrolide antibiotics and protease inhibitors.', NULL, 'Given the potential for ergot toxicity characterized by peripheral vasospasm, ischemia, thrombosis, tachycardia and hypertension, concomitant use of ergot derivatives with potent CYP450 3A4 inhibitors is considered contraindicated.', NULL, 'Given the potential for ergot toxicity characterized by peripheral vasospasm, ischemia, thrombosis, tachycardia and hypertension, concomitant use of ergot derivatives with potent CYP450 3A4 inhibitors is considered contraindicated.', 'Metabolism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511057, 'Idelalisib', 'Flurazepam', 'Moderate', 'Coadministration with idelalisib may increase the plasma concentrations of drugs that are substrates of CYP450 3A4. Idelalisib has been shown to be a potent inhibitor of this isoenzyme.', NULL, 'Use of idelalisib should generally be avoided with drugs that are primarily metabolized by CYP450 3A4, particularly those with a narrow therapeutic range (e.', NULL, 'Use of idelalisib should generally be avoided with drugs that are primarily metabolized by CYP450 3A4, particularly those with a narrow therapeutic range (e.g., antiarrhythmics, anticonvulsants, antineoplastics, immunosuppressants) or those that are considered sensitive substrates (e.g., ergot derivatives, statins, oral midazolam, triazolam). Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever idelalisib is added to or withdrawn from therapy, if coadministration is required.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511058, 'Idelalisib', 'Grepafloxacin', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 and/or P-glycoprotein (P-gp) may increase the plasma concentrations of idelalisib, which is a substrate of both the isoenzyme and efflux transporter.', NULL, 'Caution is advised if idelalisib is prescribed in combination with CYP450 3A4 and/or P-gp inhibitors.', NULL, 'Caution is advised if idelalisib is prescribed in combination with CYP450 3A4 and/or P-gp inhibitors. Pharmacologic response to idelalisib should be monitored more closely whenever a CYP450 3A4/P-gp inhibitor is added to or withdrawn from therapy, and the idelalisib dosing adjusted or interrupted as necessary in accordance with the product labeling. Patients should be closely monitored for idelalisib toxicity such as hepatotoxicity, diarrhea, colitis, intestinal perforation, pneumonitis, neutropenia, and thrombocytopenia.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511059, 'Idelalisib', 'Halofantrine', 'Major', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of halofantrine, resulting in an increased risk of QT interval prolongation and ventricular arrhythmias. The mechanism is inhibition of CYP450 3A4, the isoenzyme responsible for the metabolic clearance of halofantrine. Halofantrine has been associated with QT interval prolongation, ventricular arrhythmias, and sudden death, even at recommended dosages.', NULL, 'Caution and close monitoring is recommended if halofantrine is prescribed with CYP450 3A4 inhibitors, particularly potent ones like itraconazole, ketoconazole, posaconazole, voriconazole, clarithromycin, telithromycin, conivaptan, idelalisib, nefazodone, cobicistat, delavirdine, and most protease inhibitors.', NULL, 'Caution and close monitoring is recommended if halofantrine is prescribed with CYP450 3A4 inhibitors, particularly potent ones like itraconazole, ketoconazole, posaconazole, voriconazole, clarithromycin, telithromycin, conivaptan, idelalisib, nefazodone, cobicistat, delavirdine, and most protease inhibitors. The manufacturer recommends performing an ECG before initiating halofantrine therapy and cardiac monitoring during and for 8 to 12 hours after completion of therapy.', 'Metabolism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511060, 'Idelalisib', 'Halothane', 'Moderate', 'Coadministration with idelalisib may increase the plasma concentrations of drugs that are substrates of CYP450 3A4. Idelalisib has been shown to be a potent inhibitor of this isoenzyme.', NULL, 'Use of idelalisib should generally be avoided with drugs that are primarily metabolized by CYP450 3A4, particularly those with a narrow therapeutic range (e.', NULL, 'Use of idelalisib should generally be avoided with drugs that are primarily metabolized by CYP450 3A4, particularly those with a narrow therapeutic range (e.g., antiarrhythmics, anticonvulsants, antineoplastics, immunosuppressants) or those that are considered sensitive substrates (e.g., ergot derivatives, statins, oral midazolam, triazolam). Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever idelalisib is added to or withdrawn from therapy, if coadministration is required.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511061, 'Idelalisib', 'Iloperidone', 'Major', 'Coadministration with inhibitors of CYP450 3A4 and/or 2D6 may increase the plasma concentrations of iloperidone, which is a substrate of the isoenzymes.', NULL, 'The dosage of iloperidone should be reduced by one-half when administered concomitantly with potent CYP450 3A4 inhibitors (e.', NULL, 'The dosage of iloperidone should be reduced by one-half when administered concomitantly with potent CYP450 3A4 inhibitors (e.g., itraconazole, ketoconazole, voriconazole, nefazodone, delavirdine, protease inhibitors, clarithromycin, telithromycin) and/or potent CYP450 2D6 inhibitors (e.g., dacomitinib, fluoxetine, paroxetine, quinidine). Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, palpitations, or syncope. Following discontinuation of the potent CYP450 3A4 or 2D6 inhibitor, the iloperidone dosage should be returned to the previous level.', 'Metabolism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511062, 'Imatinib', 'Idelalisib', 'Moderate', 'Coadministration of idelalisib with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. The use of idelalisib has been associated with elevations in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) greater than 5 times the upper limit of normal. The risk and/or severity of diarrhea may be increased when idelalisib is used with other agents that cause diarrhea.', NULL, 'The use of idelalisib with other agents that can induce hepatotoxicity and/or diarrhea should be avoided whenever possible.', NULL, 'The use of idelalisib with other agents that can induce hepatotoxicity and/or diarrhea should be avoided whenever possible. Patients treated with idelalisib should be monitored for development of severe diarrhea or colitis and have serum ALT, AST, and bilirubin measured prior to initiation of treatment and regularly during treatment in accordance with the product labeling, and the dosing adjusted or interrupted as necessary. Permanent discontinuation of idelalisib is recommended in those who experience recurrent hepatotoxicity following dosage reduction and/or life-threatening diarrhea or intestinal perforation. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Patients should also contact their physician immediately if the number of bowel movements per day increases by six or more, or if they have new or worsening abdominal pain, chills, fever, nausea, or vomiting.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511063, 'Indacaterol', 'Idelalisib', 'Minor', 'Coadministration with inhibitors of CYP450 3A4 and/or P-glycoprotein may increase the systemic exposure to indacaterol following oral inhalation, as it is a substrate of both the isoenzyme and efflux transporter.', NULL, '-', NULL, '-', 'Metabolism', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511064, 'Indinavir', 'Idelalisib', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 and/or P-glycoprotein (P-gp) may increase the plasma concentrations of idelalisib, which is a substrate of both the isoenzyme and efflux transporter.', NULL, 'Caution is advised if idelalisib is prescribed in combination with CYP450 3A4 and/or P-gp inhibitors.', NULL, 'Caution is advised if idelalisib is prescribed in combination with CYP450 3A4 and/or P-gp inhibitors. Pharmacologic response to idelalisib should be monitored more closely whenever a CYP450 3A4/P-gp inhibitor is added to or withdrawn from therapy, and the idelalisib dosing adjusted or interrupted as necessary in accordance with the product labeling. Patients should be closely monitored for idelalisib toxicity such as hepatotoxicity, diarrhea, colitis, intestinal perforation, pneumonitis, neutropenia, and thrombocytopenia.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511065, 'Indomethacin', 'Idelalisib', 'Moderate', 'Coadministration of idelalisib with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. The use of idelalisib has been associated with elevations in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) greater than 5 times the upper limit of normal.', NULL, 'The use of idelalisib with other potentially hepatotoxic agents should be avoided whenever possible (e.', NULL, 'The use of idelalisib with other potentially hepatotoxic agents should be avoided whenever possible (e.g., acetaminophen; alcohol; amiodarone; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; methotrexate; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; tetracyclines; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients treated with idelalisib should have serum ALT, AST, and bilirubin measured prior to initiation of treatment and regularly during treatment in accordance with the product labeling, and the dosing adjusted or interrupted as necessary.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511066, 'Infliximab', 'Idelalisib', 'Major', 'The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Serious infections and sepsis, including fatalities, have been reported with the use of TNF blockers, particularly in patients on concomitant immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids. Concomitant use of TNF blockers with other immunosuppressants such as azathioprine or mercaptopurine may also increase the risk of a rare and often fatal cancer of white blood cells known as hepatosplenic T-Cell lymphoma (HSTCL).', NULL, 'Patients receiving a TNF blocker alone or with other immunosuppressive or myelosuppressive agents should be monitored closely for the development of infections.', NULL, 'Patients receiving a TNF blocker alone or with other immunosuppressive or myelosuppressive agents should be monitored closely for the development of infections. TNF blocker therapy should be discontinued if a serious infection or sepsis occurs. Close monitoring for signs and symptoms of HSTCL (e.g., splenomegaly, hepatomegaly, abdominal pain, persistent fever, night sweats, weight loss) is also recommended during use of TNF blockers, particularly in combination with other immunosuppressants such as azathioprine and mercaptopurine.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511067, 'Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)', 'Idelalisib', 'Moderate', 'The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.', NULL, 'In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.', NULL, 'In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin''s disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.', 'Antagonism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511068, 'Influenza A virus A/Vietnam/1194/2004 (H5N1) antigen (formaldehyde inactivated)', 'Idelalisib', 'Moderate', 'The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.', NULL, 'In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.', NULL, 'In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin''s disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.', 'Antagonism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511069, 'Interferon alfa-2a, Recombinant', 'Idelalisib', 'Moderate', 'Coadministration of idelalisib with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. The use of idelalisib has been associated with elevations in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) greater than 5 times the upper limit of normal. The risk and/or severity of diarrhea may be increased when idelalisib is used with other agents that cause diarrhea.', NULL, 'The use of idelalisib with other agents that can induce hepatotoxicity and/or diarrhea should be avoided whenever possible.', NULL, 'The use of idelalisib with other agents that can induce hepatotoxicity and/or diarrhea should be avoided whenever possible. Patients treated with idelalisib should be monitored for development of severe diarrhea or colitis and have serum ALT, AST, and bilirubin measured prior to initiation of treatment and regularly during treatment in accordance with the product labeling, and the dosing adjusted or interrupted as necessary. Permanent discontinuation of idelalisib is recommended in those who experience recurrent hepatotoxicity following dosage reduction and/or life-threatening diarrhea or intestinal perforation. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Patients should also contact their physician immediately if the number of bowel movements per day increases by six or more, or if they have new or worsening abdominal pain, chills, fever, nausea, or vomiting.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511070, 'Interferon alfa-n1', 'Idelalisib', 'Moderate', 'Coadministration of idelalisib with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. The use of idelalisib has been associated with elevations in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) greater than 5 times the upper limit of normal.', NULL, 'The use of idelalisib with other potentially hepatotoxic agents should be avoided whenever possible (e.', NULL, 'The use of idelalisib with other potentially hepatotoxic agents should be avoided whenever possible (e.g., acetaminophen; alcohol; amiodarone; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; methotrexate; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; tetracyclines; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients treated with idelalisib should have serum ALT, AST, and bilirubin measured prior to initiation of treatment and regularly during treatment in accordance with the product labeling, and the dosing adjusted or interrupted as necessary.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511071, 'Interferon alfacon-1', 'Idelalisib', 'Moderate', 'Coadministration of idelalisib with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. The use of idelalisib has been associated with elevations in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) greater than 5 times the upper limit of normal.', NULL, 'The use of idelalisib with other potentially hepatotoxic agents should be avoided whenever possible (e.', NULL, 'The use of idelalisib with other potentially hepatotoxic agents should be avoided whenever possible (e.g., acetaminophen; alcohol; amiodarone; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; methotrexate; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; tetracyclines; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients treated with idelalisib should have serum ALT, AST, and bilirubin measured prior to initiation of treatment and regularly during treatment in accordance with the product labeling, and the dosing adjusted or interrupted as necessary.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511072, 'Idelalisib', 'Tositumomab (I-131)', 'Moderate', 'The risk and/or severity of diarrhea may be increased when idelalisib is used with other agents that cause diarrhea.', NULL, 'Concomitant use of idelalisib with other drugs that cause diarrhea should be avoided whenever possible.', NULL, 'Concomitant use of idelalisib with other drugs that cause diarrhea should be avoided whenever possible. Patients treated with idelalisib should be monitored for development of severe diarrhea or colitis during treatment in accordance with the product labeling, and the dosing adjusted or interrupted as necessary. Permanent discontinuation of idelalisib is recommended in those who experience life-threatening diarrhea or intestinal perforation.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511073, 'Irinotecan (liposomal)', 'Idelalisib', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of irinotecan and its active metabolite, SN-38. CYP450 3A4 is the isoenzyme responsible for the metabolic conversion of irinotecan to its inactive metabolite, APC. Inhibition of APC formation results in more irinotecan metabolism to SN-38, an active and toxic metabolite. High plasma levels of irinotecan and SN-38 may increase the risk of potentially fatal toxicities such as severe diarrhea, neutropenia, sepsis, and thromboembolism.', NULL, 'Concomitant use of irinotecan with potent CYP450 3A4 inhibitors should generally be avoided.', NULL, 'Concomitant use of irinotecan with potent CYP450 3A4 inhibitors should generally be avoided. Potent CYP450 3A4 inhibitors should be discontinued for at least one week before initiation of treatment with irinotecan.', 'Metabolism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511074, 'Isoniazid', 'Idelalisib', 'Moderate', 'Coadministration of idelalisib with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. The use of idelalisib has been associated with elevations in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) greater than 5 times the upper limit of normal.', NULL, 'The use of idelalisib with other potentially hepatotoxic agents should be avoided whenever possible (e.', NULL, 'The use of idelalisib with other potentially hepatotoxic agents should be avoided whenever possible (e.g., acetaminophen; alcohol; amiodarone; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; methotrexate; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; tetracyclines; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients treated with idelalisib should have serum ALT, AST, and bilirubin measured prior to initiation of treatment and regularly during treatment in accordance with the product labeling, and the dosing adjusted or interrupted as necessary.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511075, 'Idelalisib', 'Kava', 'Moderate', 'Coadministration of idelalisib with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. The use of idelalisib has been associated with elevations in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) greater than 5 times the upper limit of normal.', NULL, 'The use of idelalisib with other potentially hepatotoxic agents should be avoided whenever possible (e.', NULL, 'The use of idelalisib with other potentially hepatotoxic agents should be avoided whenever possible (e.g., acetaminophen; alcohol; amiodarone; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; methotrexate; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; tetracyclines; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients treated with idelalisib should have serum ALT, AST, and bilirubin measured prior to initiation of treatment and regularly during treatment in accordance with the product labeling, and the dosing adjusted or interrupted as necessary.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511076, 'Idelalisib', 'Lactobacillus acidophilus', 'Moderate', 'Probiotic use during immunosuppressant or intense antineoplastic therapy may theoretically increase the risk of infections from the live microorganisms contained in probiotic products. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.', NULL, 'Caution is advised when probiotics are used during immunosuppressant or intense antineoplastic therapy.', NULL, 'Caution is advised when probiotics are used during immunosuppressant or intense antineoplastic therapy. It may be advisable to avoid using probiotics, particularly products containing saccharomyces boulardii, in patients who are significantly immunosuppressed.', 'Others', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511077, 'Idelalisib', 'Levobupivacaine', 'Moderate', 'Coadministration with inhibitors of CYP450 1A2 and/or 3A4 may increase the plasma concentrations of levobupivacaine, which is primarily metabolized by these isoenzymes.', NULL, 'Caution may be advisable if levobupivacaine is administered to patients receiving inhibitors of CYP450 1A2 (e.', NULL, 'Caution may be advisable if levobupivacaine is administered to patients receiving inhibitors of CYP450 1A2 (e.g., quinolones, deferasirox, mexiletine, propafenone, ticlopidine, zileuton) or CYP450 3A4 (e.g., azole antifungals, macrolide antibiotics, protease inhibitors, kinase inhibitors, aprepitant, conivaptan, cyclosporine, delavirdine, diltiazem, nefazodone, verapamil). Particular caution and dosage adjustment of levobupivacaine may be warranted during concomitant use of both a CYP450 1A2 inhibitor and a CYP450 3A4 inhibitor, or a drug that inhibits both isoenzymes (e.g., fluvoxamine). Patients should be monitored for early signs and symptoms of central nervous system toxicity such as dizziness, drowsiness, lightheadedness, anxiety, restlessness, incoherent speech, tremors, twitching, numbness and tingling of the mouth and lips, metallic taste, tinnitus, and blurred vision, as well as more serious reactions including convulsions, hypotension, arrhythmias, and cardiorespiratory depression.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511078, 'Idelalisib', 'Levacetylmethadol', 'Major', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations and duration of action of levomethadyl acetate, which is a substrate of the isoenzyme. High plasma levels of levomethadyl acetate may increase the risk of QT interval prolongation, which is thought to be associated with serious cardiac events such as ventricular arrhythmias (e.g., torsade de pointes, ventricular tachycardia), cardiac arrest, and sudden death. Cases of QT prolongation and torsade de pointes have been reported with levomethadyl acetate alone during postmarketing use.', NULL, 'Concomitant use of levomethadyl acetate with CYP450 3A4 inhibitors is considered contraindicated.', NULL, 'Concomitant use of levomethadyl acetate with CYP450 3A4 inhibitors is considered contraindicated.', 'Metabolism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511079, 'Idelalisib', 'Lomitapide', 'Major', 'Coadministration with potent and moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of lomitapide, which is primarily metabolized by the isoenzyme.', NULL, 'Concomitant use of lomitapide with potent or moderate inhibitors of CYP450 3A4 is considered contraindicated.', NULL, 'Concomitant use of lomitapide with potent or moderate inhibitors of CYP450 3A4 is considered contraindicated. Some authorities consider concomitant administration of lomitapide and itraconazole to be contraindicated during and for 2 weeks after treatment with itraconazole.', 'Metabolism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511080, 'Idelalisib', 'Lonafarnib', 'Major', 'Coadministration with potent or moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of lonafarnib.', NULL, 'Concomitant use of lonafarnib with potent or moderate CYP450 3A4 inhibitors is considered contraindicated.', NULL, 'Concomitant use of lonafarnib with potent or moderate CYP450 3A4 inhibitors is considered contraindicated.', 'Metabolism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511081, 'Idelalisib', 'Lyme disease vaccine (recombinant OspA)', 'Moderate', 'The administration of Lyme disease vaccine to immunosuppressed patients may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.', NULL, 'The manufacturer suggests considering deferral of vaccination against Lyme disease until 3 months after discontinuation of immunosuppressive therapy.', NULL, 'The manufacturer suggests considering deferral of vaccination against Lyme disease until 3 months after discontinuation of immunosuppressive therapy. Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison''s disease).', 'Others', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511082, 'Idelalisib', 'Measles virus vaccine live attenuated', 'Major', 'The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids. These patients may also have increased adverse reactions and decreased or suboptimal immunologic response to vaccines.', NULL, 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.', NULL, 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide). Current local immunization guidelines should be consulted for recommendations.', 'Others', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511083, 'Idelalisib', 'Meclofenamic acid', 'Moderate', 'Coadministration of idelalisib with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. The use of idelalisib has been associated with elevations in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) greater than 5 times the upper limit of normal.', NULL, 'The use of idelalisib with other potentially hepatotoxic agents should be avoided whenever possible (e.', NULL, 'The use of idelalisib with other potentially hepatotoxic agents should be avoided whenever possible (e.g., acetaminophen; alcohol; amiodarone; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; methotrexate; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; tetracyclines; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients treated with idelalisib should have serum ALT, AST, and bilirubin measured prior to initiation of treatment and regularly during treatment in accordance with the product labeling, and the dosing adjusted or interrupted as necessary.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511084, 'Idelalisib', 'Mephenytoin', 'Moderate', 'Coadministration of idelalisib with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. The use of idelalisib has been associated with elevations in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) greater than 5 times the upper limit of normal.', NULL, 'The use of idelalisib with other potentially hepatotoxic agents should be avoided whenever possible (e.', NULL, 'The use of idelalisib with other potentially hepatotoxic agents should be avoided whenever possible (e.g., acetaminophen; alcohol; amiodarone; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; methotrexate; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; tetracyclines; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients treated with idelalisib should have serum ALT, AST, and bilirubin measured prior to initiation of treatment and regularly during treatment in accordance with the product labeling, and the dosing adjusted or interrupted as necessary.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511085, 'Idelalisib', 'Methysergide', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of ergot derivatives, which are primarily metabolized by the isoenzyme. The interaction has occurred in patients receiving ergotamine or dihydroergotamine with potent CYP450 3A4 inhibitors such as macrolide antibiotics and protease inhibitors.', NULL, 'Given the potential for ergot toxicity characterized by peripheral vasospasm, ischemia, thrombosis, tachycardia and hypertension, concomitant use of ergot derivatives with potent CYP450 3A4 inhibitors is considered contraindicated.', NULL, 'Given the potential for ergot toxicity characterized by peripheral vasospasm, ischemia, thrombosis, tachycardia and hypertension, concomitant use of ergot derivatives with potent CYP450 3A4 inhibitors is considered contraindicated.', 'Metabolism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511086, 'Idelalisib', 'Nafcillin', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of idelalisib, which is a substrate of the isoenzyme.', NULL, 'Patients receiving idelalisib with CYP450 3A4 inducers should be monitored for potentially diminished pharmacologic response to idelalisib.', NULL, 'Patients receiving idelalisib with CYP450 3A4 inducers should be monitored for potentially diminished pharmacologic response to idelalisib. Concomitant use should be avoided if an interaction is suspected.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511087, 'Idelalisib', 'Nicotinamide', 'Moderate', 'Coadministration of idelalisib with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. The use of idelalisib has been associated with elevations in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) greater than 5 times the upper limit of normal.', NULL, 'The use of idelalisib with other potentially hepatotoxic agents should be avoided whenever possible (e.', NULL, 'The use of idelalisib with other potentially hepatotoxic agents should be avoided whenever possible (e.g., acetaminophen; alcohol; amiodarone; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; methotrexate; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; tetracyclines; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients treated with idelalisib should have serum ALT, AST, and bilirubin measured prior to initiation of treatment and regularly during treatment in accordance with the product labeling, and the dosing adjusted or interrupted as necessary.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511088, 'Idelalisib', 'Oxytetracycline', 'Moderate', 'Coadministration of idelalisib with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. The use of idelalisib has been associated with elevations in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) greater than 5 times the upper limit of normal.', NULL, 'The use of idelalisib with other potentially hepatotoxic agents should be avoided whenever possible (e.', NULL, 'The use of idelalisib with other potentially hepatotoxic agents should be avoided whenever possible (e.g., acetaminophen; alcohol; amiodarone; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; methotrexate; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; tetracyclines; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients treated with idelalisib should have serum ALT, AST, and bilirubin measured prior to initiation of treatment and regularly during treatment in accordance with the product labeling, and the dosing adjusted or interrupted as necessary.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511089, 'Idelalisib', 'Paclitaxel (protein-bound)', 'Moderate', 'The risk and/or severity of diarrhea may be increased when idelalisib is used with other agents that cause diarrhea.', NULL, 'Concomitant use of idelalisib with other drugs that cause diarrhea should be avoided whenever possible.', NULL, 'Concomitant use of idelalisib with other drugs that cause diarrhea should be avoided whenever possible. Patients treated with idelalisib should be monitored for development of severe diarrhea or colitis during treatment in accordance with the product labeling, and the dosing adjusted or interrupted as necessary. Permanent discontinuation of idelalisib is recommended in those who experience life-threatening diarrhea or intestinal perforation.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511090, 'Idelalisib', 'Pemoline', 'Moderate', 'Coadministration of idelalisib with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. The use of idelalisib has been associated with elevations in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) greater than 5 times the upper limit of normal.', NULL, 'The use of idelalisib with other potentially hepatotoxic agents should be avoided whenever possible (e.', NULL, 'The use of idelalisib with other potentially hepatotoxic agents should be avoided whenever possible (e.g., acetaminophen; alcohol; amiodarone; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; methotrexate; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; tetracyclines; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients treated with idelalisib should have serum ALT, AST, and bilirubin measured prior to initiation of treatment and regularly during treatment in accordance with the product labeling, and the dosing adjusted or interrupted as necessary.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511091, 'Idelalisib', 'Phenylbutazone', 'Moderate', 'Coadministration of idelalisib with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. The use of idelalisib has been associated with elevations in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) greater than 5 times the upper limit of normal.', NULL, 'The use of idelalisib with other potentially hepatotoxic agents should be avoided whenever possible (e.', NULL, 'The use of idelalisib with other potentially hepatotoxic agents should be avoided whenever possible (e.g., acetaminophen; alcohol; amiodarone; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; methotrexate; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; tetracyclines; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients treated with idelalisib should have serum ALT, AST, and bilirubin measured prior to initiation of treatment and regularly during treatment in accordance with the product labeling, and the dosing adjusted or interrupted as necessary.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511092, 'Idelalisib', 'Plicamycin', 'Moderate', 'The risk and/or severity of diarrhea may be increased when idelalisib is used with other agents that cause diarrhea.', NULL, 'Concomitant use of idelalisib with other drugs that cause diarrhea should be avoided whenever possible.', NULL, 'Concomitant use of idelalisib with other drugs that cause diarrhea should be avoided whenever possible. Patients treated with idelalisib should be monitored for development of severe diarrhea or colitis during treatment in accordance with the product labeling, and the dosing adjusted or interrupted as necessary. Permanent discontinuation of idelalisib is recommended in those who experience life-threatening diarrhea or intestinal perforation.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511093, 'Idelalisib', 'Polatuzumab vedotin', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may increase exposure to unconjugated monomethyl auristatin E (MMAE), the anti-mitotic and cytotoxic component of polatuzumab vedotin. Polatuzumab vedotin is an antibody-drug conjugate (ADC) that releases MMAE via proteolytic cleavage, and MMAE has been shown in vitro to be primarily metabolized by CYP450 3A4.', NULL, 'Caution is advised when polatuzumab vedotin is used concomitantly with potent CYP450 3A4 inhibitors.', NULL, 'Caution is advised when polatuzumab vedotin is used concomitantly with potent CYP450 3A4 inhibitors. Patients should be closely monitored for development or exacerbation of toxicities such as peripheral neuropathy, myelosuppression, opportunistic infections, tumor lysis syndrome and hepatotoxicity, and the dosing of polatuzumab vedotin adjusted or withheld as necessary in accordance with the product labeling.', 'Metabolism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511094, 'Idelalisib', 'Propylthiouracil', 'Moderate', 'Coadministration of idelalisib with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. The use of idelalisib has been associated with elevations in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) greater than 5 times the upper limit of normal.', NULL, 'The use of idelalisib with other potentially hepatotoxic agents should be avoided whenever possible (e.', NULL, 'The use of idelalisib with other potentially hepatotoxic agents should be avoided whenever possible (e.g., acetaminophen; alcohol; amiodarone; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; methotrexate; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; tetracyclines; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients treated with idelalisib should have serum ALT, AST, and bilirubin measured prior to initiation of treatment and regularly during treatment in accordance with the product labeling, and the dosing adjusted or interrupted as necessary.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511095, 'Idelalisib', 'Pyrazinamide', 'Moderate', 'Coadministration of idelalisib with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. The use of idelalisib has been associated with elevations in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) greater than 5 times the upper limit of normal.', NULL, 'The use of idelalisib with other potentially hepatotoxic agents should be avoided whenever possible (e.', NULL, 'The use of idelalisib with other potentially hepatotoxic agents should be avoided whenever possible (e.g., acetaminophen; alcohol; amiodarone; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; methotrexate; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; tetracyclines; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients treated with idelalisib should have serum ALT, AST, and bilirubin measured prior to initiation of treatment and regularly during treatment in accordance with the product labeling, and the dosing adjusted or interrupted as necessary.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511096, 'Idelalisib', 'Quinidine', 'Moderate', 'Coadministration with idelalisib may increase the plasma concentrations of drugs that are substrates of CYP450 3A4. Idelalisib has been shown to be a potent inhibitor of this isoenzyme.', NULL, 'Use of idelalisib should generally be avoided with drugs that are primarily metabolized by CYP450 3A4, particularly those with a narrow therapeutic range (e.', NULL, 'Use of idelalisib should generally be avoided with drugs that are primarily metabolized by CYP450 3A4, particularly those with a narrow therapeutic range (e.g., antiarrhythmics, anticonvulsants, antineoplastics, immunosuppressants) or those that are considered sensitive substrates (e.g., ergot derivatives, statins, oral midazolam, triazolam). Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever idelalisib is added to or withdrawn from therapy, if coadministration is required.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511097, 'Idelalisib', 'Riociguat', 'Moderate', 'Coadministration with potent inhibitors of CYP450 3A4 or moderate to potent inhibitors of P-glycoprotein (P-gp) or breast cancer resistant protein (BCRP) may increase the plasma concentrations of riociguat, which is partially metabolized by CYP450 3A and also a substrate of the P-gp and BCRP efflux transporters. Increased levels of riociguat may increase the risk for hypotension.', NULL, 'Caution is advised when riociguat is prescribed with potent CYP450 3A4 inhibitors or moderate to potent P-gp or BCRP inhibitors.', NULL, 'Caution is advised when riociguat is prescribed with potent CYP450 3A4 inhibitors or moderate to potent P-gp or BCRP inhibitors. Patients should be monitored for signs and symptoms of hypotension, and the dosage of riociguat adjusted if necessary.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511098, 'Idelalisib', 'Rofecoxib', 'Moderate', 'Coadministration of idelalisib with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. The use of idelalisib has been associated with elevations in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) greater than 5 times the upper limit of normal.', NULL, 'The use of idelalisib with other potentially hepatotoxic agents should be avoided whenever possible (e.', NULL, 'The use of idelalisib with other potentially hepatotoxic agents should be avoided whenever possible (e.g., acetaminophen; alcohol; amiodarone; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; methotrexate; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; tetracyclines; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients treated with idelalisib should have serum ALT, AST, and bilirubin measured prior to initiation of treatment and regularly during treatment in accordance with the product labeling, and the dosing adjusted or interrupted as necessary.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511099, 'Idelalisib', 'Rubella virus vaccine', 'Major', 'The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids. These patients may also have increased adverse reactions and decreased or suboptimal immunologic response to vaccines.', NULL, 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.', NULL, 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide). Current local immunization guidelines should be consulted for recommendations.', 'Others', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511100, 'Idelalisib', 'Pfizer-BioNTech Covid-19 Vaccine', 'Moderate', 'The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.', NULL, 'In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.', NULL, 'In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin''s disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.', 'Antagonism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511101, 'Idelalisib', 'Sibutramine', 'Minor', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of sibutramine and its active metabolites, which are metabolized by the isoenzyme. Inhibitors such as ketoconazole, cimetidine, and erythromycin have caused moderate increases in the peak plasma concentration (Cmax) and area under the concentration-time curve (AUC) of the active metabolites.', NULL, '-', NULL, '-', 'Metabolism', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511102, 'Idelalisib', 'Smallpox (Vaccinia) Vaccine, Live', 'Major', 'The administration of live smallpox virus vaccine during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.', NULL, 'Routine, nonemergency smallpox vaccination is contraindicated in patients receiving immunosuppressive therapy or cancer chemotherapy.', NULL, 'Routine, nonemergency smallpox vaccination is contraindicated in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued for at least 3 months in most cases. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide).', 'Others', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511103, 'Idelalisib', 'Sodium phosphate, monobasic (p32)', 'Moderate', 'The concomitant use of bone marrow depressants and sodium phosphate P-32 may have additive myelosuppressive effects.', NULL, 'Patients should be monitored for excessive bone marrow suppression during treatment with sodium phosphate P-32.', NULL, 'Patients should be monitored for excessive bone marrow suppression during treatment with sodium phosphate P-32. Dose reductions of the other bone marrow depressants may be necessary. Patients should be advised to contact their physician if they develop signs and symptoms of myelosuppression such as pallor, dizziness, fatigue, lethargy, fainting, easy bruising or bleeding, or signs of infection such as fever, chills, sore throat, body aches, and other influenza-like symptoms.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511104, 'Idelalisib', 'Somapacitan', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of idelalisib, which is a substrate of the isoenzyme.', NULL, 'Patients receiving idelalisib with CYP450 3A4 inducers should be monitored for potentially diminished pharmacologic response to idelalisib.', NULL, 'Patients receiving idelalisib with CYP450 3A4 inducers should be monitored for potentially diminished pharmacologic response to idelalisib. Concomitant use should be avoided if an interaction is suspected.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511105, 'Idelalisib', 'Somatrem', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of idelalisib, which is a substrate of the isoenzyme.', NULL, 'Patients receiving idelalisib with CYP450 3A4 inducers should be monitored for potentially diminished pharmacologic response to idelalisib.', NULL, 'Patients receiving idelalisib with CYP450 3A4 inducers should be monitored for potentially diminished pharmacologic response to idelalisib. Concomitant use should be avoided if an interaction is suspected.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511106, 'Idelalisib', 'St. John''s Wort', 'Major', 'Coadministration with potent inducers of CYP450 3A4 and/or P-glycoprotein (P-gp) may significantly decrease the plasma concentrations of idelalisib, which is a substrate of both the isoenzyme and efflux transporter.', NULL, 'Concomitant use of idelalisib with potent CYP450 3A4 or P-gp inducers such as carbamazepine, enzalutamide, mitotane, phenobarbital, phenytoin, rifampin, and St.', NULL, 'Concomitant use of idelalisib with potent CYP450 3A4 or P-gp inducers such as carbamazepine, enzalutamide, mitotane, phenobarbital, phenytoin, rifampin, and St. John''s wort should generally be avoided due to the potential for reduced efficacy.', 'Metabolism, Excretion', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511107, 'Idelalisib', 'Stanozolol', 'Moderate', 'Coadministration of idelalisib with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. The use of idelalisib has been associated with elevations in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) greater than 5 times the upper limit of normal.', NULL, 'The use of idelalisib with other potentially hepatotoxic agents should be avoided whenever possible (e.', NULL, 'The use of idelalisib with other potentially hepatotoxic agents should be avoided whenever possible (e.g., acetaminophen; alcohol; amiodarone; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; methotrexate; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; tetracyclines; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients treated with idelalisib should have serum ALT, AST, and bilirubin measured prior to initiation of treatment and regularly during treatment in accordance with the product labeling, and the dosing adjusted or interrupted as necessary.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511108, 'Idelalisib', 'Sulfadiazine', 'Moderate', 'Coadministration of idelalisib with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. The use of idelalisib has been associated with elevations in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) greater than 5 times the upper limit of normal.', NULL, 'The use of idelalisib with other potentially hepatotoxic agents should be avoided whenever possible (e.', NULL, 'The use of idelalisib with other potentially hepatotoxic agents should be avoided whenever possible (e.g., acetaminophen; alcohol; amiodarone; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; methotrexate; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; tetracyclines; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients treated with idelalisib should have serum ALT, AST, and bilirubin measured prior to initiation of treatment and regularly during treatment in accordance with the product labeling, and the dosing adjusted or interrupted as necessary.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511109, 'Idelalisib', 'Sulfadoxine', 'Moderate', 'Coadministration of idelalisib with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. The use of idelalisib has been associated with elevations in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) greater than 5 times the upper limit of normal.', NULL, 'The use of idelalisib with other potentially hepatotoxic agents should be avoided whenever possible (e.', NULL, 'The use of idelalisib with other potentially hepatotoxic agents should be avoided whenever possible (e.g., acetaminophen; alcohol; amiodarone; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; methotrexate; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; tetracyclines; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients treated with idelalisib should have serum ALT, AST, and bilirubin measured prior to initiation of treatment and regularly during treatment in accordance with the product labeling, and the dosing adjusted or interrupted as necessary.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511110, 'Idelalisib', 'Sulfamethizole', 'Moderate', 'Coadministration of idelalisib with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. The use of idelalisib has been associated with elevations in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) greater than 5 times the upper limit of normal.', NULL, 'The use of idelalisib with other potentially hepatotoxic agents should be avoided whenever possible (e.', NULL, 'The use of idelalisib with other potentially hepatotoxic agents should be avoided whenever possible (e.g., acetaminophen; alcohol; amiodarone; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; methotrexate; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; tetracyclines; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients treated with idelalisib should have serum ALT, AST, and bilirubin measured prior to initiation of treatment and regularly during treatment in accordance with the product labeling, and the dosing adjusted or interrupted as necessary.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511111, 'Idelalisib', 'Sulfinpyrazone', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of idelalisib, which is a substrate of the isoenzyme.', NULL, 'Patients receiving idelalisib with CYP450 3A4 inducers should be monitored for potentially diminished pharmacologic response to idelalisib.', NULL, 'Patients receiving idelalisib with CYP450 3A4 inducers should be monitored for potentially diminished pharmacologic response to idelalisib. Concomitant use should be avoided if an interaction is suspected.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511112, 'Idelalisib', 'Sulfisoxazole', 'Moderate', 'Coadministration of idelalisib with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. The use of idelalisib has been associated with elevations in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) greater than 5 times the upper limit of normal.', NULL, 'The use of idelalisib with other potentially hepatotoxic agents should be avoided whenever possible (e.', NULL, 'The use of idelalisib with other potentially hepatotoxic agents should be avoided whenever possible (e.g., acetaminophen; alcohol; amiodarone; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; methotrexate; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; tetracyclines; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients treated with idelalisib should have serum ALT, AST, and bilirubin measured prior to initiation of treatment and regularly during treatment in accordance with the product labeling, and the dosing adjusted or interrupted as necessary.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511113, 'Idelalisib', 'Tacrine', 'Moderate', 'Coadministration of idelalisib with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. The use of idelalisib has been associated with elevations in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) greater than 5 times the upper limit of normal.', NULL, 'The use of idelalisib with other potentially hepatotoxic agents should be avoided whenever possible (e.', NULL, 'The use of idelalisib with other potentially hepatotoxic agents should be avoided whenever possible (e.g., acetaminophen; alcohol; amiodarone; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; methotrexate; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; tetracyclines; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients treated with idelalisib should have serum ALT, AST, and bilirubin measured prior to initiation of treatment and regularly during treatment in accordance with the product labeling, and the dosing adjusted or interrupted as necessary.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511114, 'Idelalisib', 'Telaprevir', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 and/or P-glycoprotein (P-gp) may increase the plasma concentrations of idelalisib, which is a substrate of both the isoenzyme and efflux transporter.', NULL, 'Caution is advised if idelalisib is prescribed in combination with CYP450 3A4 and/or P-gp inhibitors.', NULL, 'Caution is advised if idelalisib is prescribed in combination with CYP450 3A4 and/or P-gp inhibitors. Pharmacologic response to idelalisib should be monitored more closely whenever a CYP450 3A4/P-gp inhibitor is added to or withdrawn from therapy, and the idelalisib dosing adjusted or interrupted as necessary in accordance with the product labeling. Patients should be closely monitored for idelalisib toxicity such as hepatotoxicity, diarrhea, colitis, intestinal perforation, pneumonitis, neutropenia, and thrombocytopenia.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511115, 'Idelalisib', 'Terfenadine', 'Moderate', 'Coadministration with idelalisib may increase the plasma concentrations of drugs that are substrates of CYP450 3A4. Idelalisib has been shown to be a potent inhibitor of this isoenzyme.', NULL, 'Use of idelalisib should generally be avoided with drugs that are primarily metabolized by CYP450 3A4, particularly those with a narrow therapeutic range (e.', NULL, 'Use of idelalisib should generally be avoided with drugs that are primarily metabolized by CYP450 3A4, particularly those with a narrow therapeutic range (e.g., antiarrhythmics, anticonvulsants, antineoplastics, immunosuppressants) or those that are considered sensitive substrates (e.g., ergot derivatives, statins, oral midazolam, triazolam). Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever idelalisib is added to or withdrawn from therapy, if coadministration is required.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511116, 'Idelalisib', 'Testosterone (topical)', 'Moderate', 'Coadministration of idelalisib with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. The use of idelalisib has been associated with elevations in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) greater than 5 times the upper limit of normal.', NULL, 'The use of idelalisib with other potentially hepatotoxic agents should be avoided whenever possible (e.', NULL, 'The use of idelalisib with other potentially hepatotoxic agents should be avoided whenever possible (e.g., acetaminophen; alcohol; amiodarone; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; methotrexate; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; tetracyclines; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients treated with idelalisib should have serum ALT, AST, and bilirubin measured prior to initiation of treatment and regularly during treatment in accordance with the product labeling, and the dosing adjusted or interrupted as necessary.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511117, 'Idelalisib', 'Tisagenlecleucel', 'Moderate', 'The risk and/or severity of diarrhea may be increased when idelalisib is used with other agents that cause diarrhea.', NULL, 'Concomitant use of idelalisib with other drugs that cause diarrhea should be avoided whenever possible.', NULL, 'Concomitant use of idelalisib with other drugs that cause diarrhea should be avoided whenever possible. Patients treated with idelalisib should be monitored for development of severe diarrhea or colitis during treatment in accordance with the product labeling, and the dosing adjusted or interrupted as necessary. Permanent discontinuation of idelalisib is recommended in those who experience life-threatening diarrhea or intestinal perforation.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511118, 'Idelalisib', 'Tolmetin', 'Moderate', 'Coadministration of idelalisib with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. The use of idelalisib has been associated with elevations in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) greater than 5 times the upper limit of normal.', NULL, 'The use of idelalisib with other potentially hepatotoxic agents should be avoided whenever possible (e.', NULL, 'The use of idelalisib with other potentially hepatotoxic agents should be avoided whenever possible (e.g., acetaminophen; alcohol; amiodarone; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; methotrexate; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; tetracyclines; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients treated with idelalisib should have serum ALT, AST, and bilirubin measured prior to initiation of treatment and regularly during treatment in accordance with the product labeling, and the dosing adjusted or interrupted as necessary.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511119, 'Idelalisib', 'Tositumomab', 'Moderate', 'The risk and/or severity of diarrhea may be increased when idelalisib is used with other agents that cause diarrhea.', NULL, 'Concomitant use of idelalisib with other drugs that cause diarrhea should be avoided whenever possible.', NULL, 'Concomitant use of idelalisib with other drugs that cause diarrhea should be avoided whenever possible. Patients treated with idelalisib should be monitored for development of severe diarrhea or colitis during treatment in accordance with the product labeling, and the dosing adjusted or interrupted as necessary. Permanent discontinuation of idelalisib is recommended in those who experience life-threatening diarrhea or intestinal perforation.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511120, 'Idelalisib', 'Trichophyton mentagrophytes', 'Moderate', 'Immunosuppressed patients may have diminished response to diagnostic skin test antigens due to suppression of cell-mediated, delayed-type hypersensitivity. Falsely insignificant or false-negative results may occur in such patients, which may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.', NULL, 'Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.', NULL, 'Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.', 'Others', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511121, 'Idelalisib', 'Trimetrexate', 'Moderate', 'Coadministration of idelalisib with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. The use of idelalisib has been associated with elevations in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) greater than 5 times the upper limit of normal.', NULL, 'The use of idelalisib with other potentially hepatotoxic agents should be avoided whenever possible (e.', NULL, 'The use of idelalisib with other potentially hepatotoxic agents should be avoided whenever possible (e.g., acetaminophen; alcohol; amiodarone; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; methotrexate; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; tetracyclines; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients treated with idelalisib should have serum ALT, AST, and bilirubin measured prior to initiation of treatment and regularly during treatment in accordance with the product labeling, and the dosing adjusted or interrupted as necessary.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511122, 'Idelalisib', 'Troglitazone', 'Moderate', 'Coadministration of idelalisib with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. The use of idelalisib has been associated with elevations in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) greater than 5 times the upper limit of normal.', NULL, 'The use of idelalisib with other potentially hepatotoxic agents should be avoided whenever possible (e.', NULL, 'The use of idelalisib with other potentially hepatotoxic agents should be avoided whenever possible (e.g., acetaminophen; alcohol; amiodarone; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; methotrexate; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; tetracyclines; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients treated with idelalisib should have serum ALT, AST, and bilirubin measured prior to initiation of treatment and regularly during treatment in accordance with the product labeling, and the dosing adjusted or interrupted as necessary.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511123, 'Idelalisib', 'Troleandomycin', 'Moderate', 'Coadministration of idelalisib with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. The use of idelalisib has been associated with elevations in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) greater than 5 times the upper limit of normal. Coadministration with inhibitors of CYP450 3A4 and/or P-glycoprotein (P-gp) may increase the plasma concentrations of idelalisib, which is a substrate of both the isoenzyme and efflux transporter.', NULL, 'The use of idelalisib with other potentially hepatotoxic agents such as azole antifungal agents, macrolide antibiotics, nefazodone, ritonavir, and telithromycin should be avoided whenever possible.', NULL, 'The use of idelalisib with other potentially hepatotoxic agents such as azole antifungal agents, macrolide antibiotics, nefazodone, ritonavir, and telithromycin should be avoided whenever possible. In addition, these agents are potent CYP450 3A4/P-gp inhibitors and may increase the toxicity of idelalisib. Caution is advised if coadministration is required. Patients should be closely monitored for hepatotoxicity and other toxicities of idelalisib such as diarrhea, colitis, intestinal perforation, pneumonitis, neutropenia and thrombocytopenia, and the dosing adjusted or interrupted as necessary. Patients should have serum ALT, AST, and bilirubin measured prior to initiation of treatment and regularly during treatment in accordance with the product labeling. Permanent discontinuation of idelalisib is recommended in those who experience recurrent hepatotoxicity following dosage reduction. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.', 'Metabolism, Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511124, 'Idelalisib', 'Trovafloxacin', 'Moderate', 'Coadministration of idelalisib with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. The use of idelalisib has been associated with elevations in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) greater than 5 times the upper limit of normal.', NULL, 'The use of idelalisib with other potentially hepatotoxic agents should be avoided whenever possible (e.', NULL, 'The use of idelalisib with other potentially hepatotoxic agents should be avoided whenever possible (e.g., acetaminophen; alcohol; amiodarone; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; methotrexate; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; tetracyclines; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients treated with idelalisib should have serum ALT, AST, and bilirubin measured prior to initiation of treatment and regularly during treatment in accordance with the product labeling, and the dosing adjusted or interrupted as necessary.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511125, 'Idelalisib', 'Typhoid vaccine (inactivated)', 'Moderate', 'The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.', NULL, 'In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.', NULL, 'In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin''s disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.', 'Antagonism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511126, 'Idelalisib', 'Typhoid vaccine (live)', 'Major', 'The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids. These patients may also have increased adverse reactions and decreased or suboptimal immunologic response to vaccines.', NULL, 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.', NULL, 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide). Current local immunization guidelines should be consulted for recommendations.', 'Others', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511127, 'Idelalisib', 'Uracil mustard', 'Moderate', 'The risk and/or severity of diarrhea may be increased when idelalisib is used with other agents that cause diarrhea.', NULL, 'Concomitant use of idelalisib with other drugs that cause diarrhea should be avoided whenever possible.', NULL, 'Concomitant use of idelalisib with other drugs that cause diarrhea should be avoided whenever possible. Patients treated with idelalisib should be monitored for development of severe diarrhea or colitis during treatment in accordance with the product labeling, and the dosing adjusted or interrupted as necessary. Permanent discontinuation of idelalisib is recommended in those who experience life-threatening diarrhea or intestinal perforation.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511128, 'Idelalisib', 'Valdecoxib', 'Moderate', 'Coadministration of idelalisib with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. The use of idelalisib has been associated with elevations in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) greater than 5 times the upper limit of normal.', NULL, 'The use of idelalisib with other potentially hepatotoxic agents should be avoided whenever possible (e.', NULL, 'The use of idelalisib with other potentially hepatotoxic agents should be avoided whenever possible (e.g., acetaminophen; alcohol; amiodarone; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; methotrexate; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; tetracyclines; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients treated with idelalisib should have serum ALT, AST, and bilirubin measured prior to initiation of treatment and regularly during treatment in accordance with the product labeling, and the dosing adjusted or interrupted as necessary.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511129, 'Idelalisib', 'Vinblastine', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 and/or P-glycoprotein may significantly increase the plasma concentrations of vinca alkaloids, which are substrates of both the hepatic microsomal isoenzyme and intracellular efflux transporter.', NULL, 'Concomitant use of vinca alkaloids with potent CYP450 3A4 and/or P-glycoprotein inhibitors should be avoided if possible.', NULL, 'Concomitant use of vinca alkaloids with potent CYP450 3A4 and/or P-glycoprotein inhibitors should be avoided if possible. Some authorities recommend avoiding concomitant use of vinca alkaloids during and for 2 weeks after treatment with itraconazole. Otherwise, conservative dosing of the antineoplastic should be considered, and the patient closely monitored for toxicity. Based on the known half-life of vinca alkaloids (24 to 48 hours), the time course of interaction is expected to be approximately 5 to 7 days. Patients should be advised to seek medical attention if they experience symptoms that could indicate neuro- or myelotoxicity, including constipation, abdominal pain or bloating, urinary retention, paresthesia, paralysis, muscle weakness, hearing loss, seizures, erratic blood pressure changes, unusual or excessive bleeding, easy bruising, pallor, fatigue, dizziness, lightheadedness, fever, chills, and sore throat. Following discontinuation of the potent CYP450 3A4 inhibitor, a washout period of approximately one week should be allowed before the antineoplastic dosage is adjusted upward to the previous dosage.', 'Metabolism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511130, 'Idelalisib', 'Vincristine (liposome)', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 and/or P-glycoprotein may significantly increase the plasma concentrations of vinca alkaloids, which are substrates of both the hepatic microsomal isoenzyme and intracellular efflux transporter.', NULL, 'Concomitant use of vinca alkaloids with potent CYP450 3A4 and/or P-glycoprotein inhibitors should be avoided if possible.', NULL, 'Concomitant use of vinca alkaloids with potent CYP450 3A4 and/or P-glycoprotein inhibitors should be avoided if possible. Some authorities recommend avoiding concomitant use of vinca alkaloids during and for 2 weeks after treatment with itraconazole. Otherwise, conservative dosing of the antineoplastic should be considered, and the patient closely monitored for toxicity. Based on the known half-life of vinca alkaloids (24 to 48 hours), the time course of interaction is expected to be approximately 5 to 7 days. Patients should be advised to seek medical attention if they experience symptoms that could indicate neuro- or myelotoxicity, including constipation, abdominal pain or bloating, urinary retention, paresthesia, paralysis, muscle weakness, hearing loss, seizures, erratic blood pressure changes, unusual or excessive bleeding, easy bruising, pallor, fatigue, dizziness, lightheadedness, fever, chills, and sore throat. Following discontinuation of the potent CYP450 3A4 inhibitor, a washout period of approximately one week should be allowed before the antineoplastic dosage is adjusted upward to the previous dosage.', 'Metabolism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511131, 'Idelalisib', 'Zalcitabine', 'Moderate', 'Coadministration of idelalisib with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. The use of idelalisib has been associated with elevations in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) greater than 5 times the upper limit of normal.', NULL, 'The use of idelalisib with other potentially hepatotoxic agents should be avoided whenever possible (e.', NULL, 'The use of idelalisib with other potentially hepatotoxic agents should be avoided whenever possible (e.g., acetaminophen; alcohol; amiodarone; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; methotrexate; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; tetracyclines; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients treated with idelalisib should have serum ALT, AST, and bilirubin measured prior to initiation of treatment and regularly during treatment in accordance with the product labeling, and the dosing adjusted or interrupted as necessary.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511132, 'Ifosfamide', 'Oxitriptan', 'Moderate', 'Centrally-acting agents such as antiemetics, sedatives, narcotics, or antihistamines may add to the neurotoxic effects of ifosfamide. Administration of ifosfamide can cause CNS toxicity, which necessitates careful monitoring of the patient. Neurologic manifestations include somnolence, confusion, hallucinations, blurred vision, psychotic behavior, extrapyramidal symptoms, urinary incontinence, seizures, and in some instances, coma. There have also been reports of peripheral neuropathy. Ifosfamide neurotoxicity may occur within a few hours to a few days after initial administration and typically resolves within 48 to 72 hours of ifosfamide discontinuation.', NULL, 'Due to the potential for additive effects, centrally-acting agents should be used with caution in combination with ifosfamide.', NULL, 'Due to the potential for additive effects, centrally-acting agents should be used with caution in combination with ifosfamide. If ifosfamide-induced encephalopathy occurs, both ifosfamide and non-essential concomitant CNS agents should be discontinued. Supportive therapy should be initiated and maintained until complete resolution of neurotoxicity.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511133, 'Ifosfamide', 'Acetohexamide', 'Moderate', 'The hypoglycemic effect of insulin secretagogues (e.g., sulfonylureas, meglitinides) may be potentiated by certain drugs, including ACE inhibitors, 4-aminoquinolines, amylin analogs, anabolic steroids, fibrates, monoamine oxidase inhibitors (MAOIs, including linezolid), nonsteroidal anti-inflammatory drugs (NSAIDs), salicylates, selective serotonin reuptake inhibitors (SSRIs), sulfonamides, disopyramide, propoxyphene, quinine, quinidine, and ginseng. These drugs may increase the risk of hypoglycemia by enhancing insulin sensitivity (ACE inhibitors, fibrates, ginseng); stimulating insulin secretion (salicylates, NSAIDs, disopyramide, quinine, quinidine, MAOIs, ginseng); decreasing insulin clearance and resistance (4-aminoquinolines); increasing peripheral glucose utilization (SSRIs, insulin-like growth factor); inhibiting gluconeogenesis (SSRIs, MAOIs, insulin-like growth factor); slowing the rate of gastric emptying (amylin analogs); and/or suppressing postprandial glucagon secretion (amylin analogs). Or, they may increase plasma concentration of insulin secretagogues by displacing them from plasma protein binding sites and/or inhibiting their metabolism (fibrates, NSAIDs, salicylates, sulfonamides).', NULL, 'Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin secretagogues, particularly in patients with advanced age and/or renal impairment.', NULL, 'Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin secretagogues, particularly in patients with advanced age and/or renal impairment. The oral antidiabetic dosage(s) may require adjustment if an interaction is suspected. Patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations), how to treat it, and to contact their doctor if it occurs. Patients should be observed for loss of glycemic control when these drugs are withdrawn.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511134, 'Ifosfamide', 'Human adenovirus e serotype 4 strain cl-68578 antigen', 'Moderate', 'There are no data regarding the use of live, unattenuated Adenovirus Type 4 and Type 7 vaccine during treatment with immunosuppressive therapies, including alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids. It is not known whether immunosuppressed patients may have an increased risk of adverse reactions or a decreased or suboptimal immunologic response to the vaccine.', NULL, 'The safety and efficacy of live, unattenuated Adenovirus Type 4 and Type 7 vaccine have not been established in patients receiving immunosuppressive therapies.', NULL, 'The safety and efficacy of live, unattenuated Adenovirus Type 4 and Type 7 vaccine have not been established in patients receiving immunosuppressive therapies. Caution is advised.', 'Others', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511135, 'Ifosfamide', 'Amikacin (liposome)', 'Moderate', 'The concurrent or sequential use of two or more potentially nephrotoxic or neurotoxic drugs may increase the risk of toxicity. Patients who are elderly, debilitated, dehydrated, or who have preexisting renal dysfunction may have a higher risk of developing adverse reactions.', NULL, 'Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.', NULL, 'Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511136, 'Ifosfamide', 'Amoxapine', 'Moderate', 'Centrally-acting agents such as antiemetics, sedatives, narcotics, or antihistamines may add to the neurotoxic effects of ifosfamide. Administration of ifosfamide can cause CNS toxicity, which necessitates careful monitoring of the patient. Neurologic manifestations include somnolence, confusion, hallucinations, blurred vision, psychotic behavior, extrapyramidal symptoms, urinary incontinence, seizures, and in some instances, coma. There have also been reports of peripheral neuropathy. Ifosfamide neurotoxicity may occur within a few hours to a few days after initial administration and typically resolves within 48 to 72 hours of ifosfamide discontinuation.', NULL, 'Due to the potential for additive effects, centrally-acting agents should be used with caution in combination with ifosfamide.', NULL, 'Due to the potential for additive effects, centrally-acting agents should be used with caution in combination with ifosfamide. If ifosfamide-induced encephalopathy occurs, both ifosfamide and non-essential concomitant CNS agents should be discontinued. Supportive therapy should be initiated and maintained until complete resolution of neurotoxicity.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511137, 'Ifosfamide', 'Amphotericin B (cholesteryl sulfate)', 'Moderate', 'The concurrent or sequential use of two or more potentially nephrotoxic or neurotoxic drugs may increase the risk of toxicity. Patients who are elderly, debilitated, dehydrated, or who have preexisting renal dysfunction may have a higher risk of developing adverse reactions.', NULL, 'Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.', NULL, 'Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511138, 'Ifosfamide', 'Amphotericin B (liposomal)', 'Moderate', 'The concurrent or sequential use of two or more potentially nephrotoxic or neurotoxic drugs may increase the risk of toxicity. Patients who are elderly, debilitated, dehydrated, or who have preexisting renal dysfunction may have a higher risk of developing adverse reactions.', NULL, 'Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.', NULL, 'Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511139, 'Ifosfamide', 'Amprenavir', 'Moderate', 'Coadministration with amprenavir or its prodrug, fosamprenavir, may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by amprenavir.', NULL, 'Caution is advised if amprenavir must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised if amprenavir must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever amprenavir is added to or withdrawn from therapy.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511140, 'Anisindione', 'Ifosfamide', 'Moderate', 'Limited data (from three patients) reveal enhanced anticoagulant activity (significantly increased INR) during chemotherapy with ifosfamide/mesna in patients previously stable on warfarin. The mechanism is not known, but is suspected to be displacement of warfarin from protein-binding sites by ifosfamide metabolites.', NULL, 'Careful and frequent monitoring of INR during coadministration is recommended.', NULL, 'Careful and frequent monitoring of INR during coadministration is recommended. Also, close monitoring is recommended when chemotherapeutic agents are discontinued, because anticoagulant effect may be decreased and the risk of thromboembolism increased. It may also be advisable to monitor patients on other anticoagulants.', 'Others', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511141, 'Ifosfamide', 'Azatadine', 'Moderate', 'Centrally-acting agents such as antiemetics, sedatives, narcotics, or antihistamines may add to the neurotoxic effects of ifosfamide. Administration of ifosfamide can cause CNS toxicity, which necessitates careful monitoring of the patient. Neurologic manifestations include somnolence, confusion, hallucinations, blurred vision, psychotic behavior, extrapyramidal symptoms, urinary incontinence, seizures, and in some instances, coma. There have also been reports of peripheral neuropathy. Ifosfamide neurotoxicity may occur within a few hours to a few days after initial administration and typically resolves within 48 to 72 hours of ifosfamide discontinuation.', NULL, 'Due to the potential for additive effects, centrally-acting agents should be used with caution in combination with ifosfamide.', NULL, 'Due to the potential for additive effects, centrally-acting agents should be used with caution in combination with ifosfamide. If ifosfamide-induced encephalopathy occurs, both ifosfamide and non-essential concomitant CNS agents should be discontinued. Supportive therapy should be initiated and maintained until complete resolution of neurotoxicity.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511142, 'Ifosfamide', 'Bacillus calmette-guerin substrain tice live antigen', 'Major', 'The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids. These patients may also have increased adverse reactions and decreased or suboptimal immunologic response to vaccines.', NULL, 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.', NULL, 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide). Current local immunization guidelines should be consulted for recommendations.', 'Others', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511143, 'Ifosfamide', 'Berotralstat', 'Moderate', 'Coadministration with berotralstat may increase the plasma concentrations and effects of drugs that are substrates of CYP450 3A4 and/or 2D6. The mechanism is decreased clearance due to inhibition of CYP450 3A4 and 2D6 activity by berotralstat.', NULL, 'Caution is advised when berotralstat is coadministered with drugs that are substrates of CYP450 3A4 and/or 2D6, particularly those with a narrow therapeutic index including but not limited to thioridazine, pimozide, cyclosporine, and fentanyl.', NULL, 'Caution is advised when berotralstat is coadministered with drugs that are substrates of CYP450 3A4 and/or 2D6, particularly those with a narrow therapeutic index including but not limited to thioridazine, pimozide, cyclosporine, and fentanyl.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511144, 'Ifosfamide', 'Bifidobacterium longum infantis', 'Moderate', 'Probiotic use during immunosuppressant or intense antineoplastic therapy may theoretically increase the risk of infections from the live microorganisms contained in probiotic products. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.', NULL, 'Caution is advised when probiotics are used during immunosuppressant or intense antineoplastic therapy.', NULL, 'Caution is advised when probiotics are used during immunosuppressant or intense antineoplastic therapy. It may be advisable to avoid using probiotics, particularly products containing saccharomyces boulardii, in patients who are significantly immunosuppressed.', 'Others', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511145, 'Ifosfamide', 'Butabarbital', 'Moderate', 'Centrally-acting agents such as antiemetics, sedatives, narcotics, or antihistamines may add to the neurotoxic effects of ifosfamide. Administration of ifosfamide can cause CNS toxicity, which necessitates careful monitoring of the patient. Neurologic manifestations include somnolence, confusion, hallucinations, blurred vision, psychotic behavior, extrapyramidal symptoms, urinary incontinence, seizures, and in some instances, coma. There have also been reports of peripheral neuropathy. Ifosfamide neurotoxicity may occur within a few hours to a few days after initial administration and typically resolves within 48 to 72 hours of ifosfamide discontinuation.', NULL, 'Due to the potential for additive effects, centrally-acting agents should be used with caution in combination with ifosfamide.', NULL, 'Due to the potential for additive effects, centrally-acting agents should be used with caution in combination with ifosfamide. If ifosfamide-induced encephalopathy occurs, both ifosfamide and non-essential concomitant CNS agents should be discontinued. Supportive therapy should be initiated and maintained until complete resolution of neurotoxicity.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511146, 'Ifosfamide', 'Candida albicans', 'Moderate', 'Immunosuppressed patients may have diminished response to diagnostic skin test antigens due to suppression of cell-mediated, delayed-type hypersensitivity. Falsely insignificant or false-negative results may occur in such patients, which may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.', NULL, 'Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.', NULL, 'Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.', 'Others', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511147, 'Ifosfamide', 'Chloral hydrate', 'Moderate', 'Centrally-acting agents such as antiemetics, sedatives, narcotics, or antihistamines may add to the neurotoxic effects of ifosfamide. Administration of ifosfamide can cause CNS toxicity, which necessitates careful monitoring of the patient. Neurologic manifestations include somnolence, confusion, hallucinations, blurred vision, psychotic behavior, extrapyramidal symptoms, urinary incontinence, seizures, and in some instances, coma. There have also been reports of peripheral neuropathy. Ifosfamide neurotoxicity may occur within a few hours to a few days after initial administration and typically resolves within 48 to 72 hours of ifosfamide discontinuation.', NULL, 'Due to the potential for additive effects, centrally-acting agents should be used with caution in combination with ifosfamide.', NULL, 'Due to the potential for additive effects, centrally-acting agents should be used with caution in combination with ifosfamide. If ifosfamide-induced encephalopathy occurs, both ifosfamide and non-essential concomitant CNS agents should be discontinued. Supportive therapy should be initiated and maintained until complete resolution of neurotoxicity.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511148, 'Ifosfamide', 'Chlorcyclizine', 'Moderate', 'Centrally-acting agents such as antiemetics, sedatives, narcotics, or antihistamines may add to the neurotoxic effects of ifosfamide. Administration of ifosfamide can cause CNS toxicity, which necessitates careful monitoring of the patient. Neurologic manifestations include somnolence, confusion, hallucinations, blurred vision, psychotic behavior, extrapyramidal symptoms, urinary incontinence, seizures, and in some instances, coma. There have also been reports of peripheral neuropathy. Ifosfamide neurotoxicity may occur within a few hours to a few days after initial administration and typically resolves within 48 to 72 hours of ifosfamide discontinuation.', NULL, 'Due to the potential for additive effects, centrally-acting agents should be used with caution in combination with ifosfamide.', NULL, 'Due to the potential for additive effects, centrally-acting agents should be used with caution in combination with ifosfamide. If ifosfamide-induced encephalopathy occurs, both ifosfamide and non-essential concomitant CNS agents should be discontinued. Supportive therapy should be initiated and maintained until complete resolution of neurotoxicity.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511149, 'Ifosfamide', 'Chlormezanone', 'Moderate', 'Centrally-acting agents such as antiemetics, sedatives, narcotics, or antihistamines may add to the neurotoxic effects of ifosfamide. Administration of ifosfamide can cause CNS toxicity, which necessitates careful monitoring of the patient. Neurologic manifestations include somnolence, confusion, hallucinations, blurred vision, psychotic behavior, extrapyramidal symptoms, urinary incontinence, seizures, and in some instances, coma. There have also been reports of peripheral neuropathy. Ifosfamide neurotoxicity may occur within a few hours to a few days after initial administration and typically resolves within 48 to 72 hours of ifosfamide discontinuation.', NULL, 'Due to the potential for additive effects, centrally-acting agents should be used with caution in combination with ifosfamide.', NULL, 'Due to the potential for additive effects, centrally-acting agents should be used with caution in combination with ifosfamide. If ifosfamide-induced encephalopathy occurs, both ifosfamide and non-essential concomitant CNS agents should be discontinued. Supportive therapy should be initiated and maintained until complete resolution of neurotoxicity.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511150, 'Ifosfamide', 'Chlorphenesin', 'Moderate', 'Centrally-acting agents such as antiemetics, sedatives, narcotics, or antihistamines may add to the neurotoxic effects of ifosfamide. Administration of ifosfamide can cause CNS toxicity, which necessitates careful monitoring of the patient. Neurologic manifestations include somnolence, confusion, hallucinations, blurred vision, psychotic behavior, extrapyramidal symptoms, urinary incontinence, seizures, and in some instances, coma. There have also been reports of peripheral neuropathy. Ifosfamide neurotoxicity may occur within a few hours to a few days after initial administration and typically resolves within 48 to 72 hours of ifosfamide discontinuation.', NULL, 'Due to the potential for additive effects, centrally-acting agents should be used with caution in combination with ifosfamide.', NULL, 'Due to the potential for additive effects, centrally-acting agents should be used with caution in combination with ifosfamide. If ifosfamide-induced encephalopathy occurs, both ifosfamide and non-essential concomitant CNS agents should be discontinued. Supportive therapy should be initiated and maintained until complete resolution of neurotoxicity.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511151, 'Ifosfamide', 'Chlorpromazine', 'Moderate', 'Centrally-acting agents such as antiemetics, sedatives, narcotics, or antihistamines may add to the neurotoxic effects of ifosfamide. Administration of ifosfamide can cause CNS toxicity, which necessitates careful monitoring of the patient. Neurologic manifestations include somnolence, confusion, hallucinations, blurred vision, psychotic behavior, extrapyramidal symptoms, urinary incontinence, seizures, and in some instances, coma. There have also been reports of peripheral neuropathy. Ifosfamide neurotoxicity may occur within a few hours to a few days after initial administration and typically resolves within 48 to 72 hours of ifosfamide discontinuation.', NULL, 'Due to the potential for additive effects, centrally-acting agents should be used with caution in combination with ifosfamide.', NULL, 'Due to the potential for additive effects, centrally-acting agents should be used with caution in combination with ifosfamide. If ifosfamide-induced encephalopathy occurs, both ifosfamide and non-essential concomitant CNS agents should be discontinued. Supportive therapy should be initiated and maintained until complete resolution of neurotoxicity.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511152, 'Ifosfamide', 'Vibrio cholerae CVD 103-HgR strain live antigen', 'Moderate', 'The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.', NULL, 'In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.', NULL, 'In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin''s disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.', 'Antagonism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511153, 'Ifosfamide', 'Cinoxacin', 'Minor', 'Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics. The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.', NULL, '-', NULL, '-', 'Absorption', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511154, 'Ifosfamide', 'Coccidioides immitis spherule', 'Moderate', 'Immunosuppressed patients may have diminished response to diagnostic skin test antigens due to suppression of cell-mediated, delayed-type hypersensitivity. Falsely insignificant or false-negative results may occur in such patients, which may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.', NULL, 'Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.', NULL, 'Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.', 'Others', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511155, 'Ifosfamide', 'Cyclizine', 'Moderate', 'Centrally-acting agents such as antiemetics, sedatives, narcotics, or antihistamines may add to the neurotoxic effects of ifosfamide. Administration of ifosfamide can cause CNS toxicity, which necessitates careful monitoring of the patient. Neurologic manifestations include somnolence, confusion, hallucinations, blurred vision, psychotic behavior, extrapyramidal symptoms, urinary incontinence, seizures, and in some instances, coma. There have also been reports of peripheral neuropathy. Ifosfamide neurotoxicity may occur within a few hours to a few days after initial administration and typically resolves within 48 to 72 hours of ifosfamide discontinuation.', NULL, 'Due to the potential for additive effects, centrally-acting agents should be used with caution in combination with ifosfamide.', NULL, 'Due to the potential for additive effects, centrally-acting agents should be used with caution in combination with ifosfamide. If ifosfamide-induced encephalopathy occurs, both ifosfamide and non-essential concomitant CNS agents should be discontinued. Supportive therapy should be initiated and maintained until complete resolution of neurotoxicity.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511156, 'Ifosfamide', 'Cyproheptadine', 'Moderate', 'Centrally-acting agents such as antiemetics, sedatives, narcotics, or antihistamines may add to the neurotoxic effects of ifosfamide. Administration of ifosfamide can cause CNS toxicity, which necessitates careful monitoring of the patient. Neurologic manifestations include somnolence, confusion, hallucinations, blurred vision, psychotic behavior, extrapyramidal symptoms, urinary incontinence, seizures, and in some instances, coma. There have also been reports of peripheral neuropathy. Ifosfamide neurotoxicity may occur within a few hours to a few days after initial administration and typically resolves within 48 to 72 hours of ifosfamide discontinuation.', NULL, 'Due to the potential for additive effects, centrally-acting agents should be used with caution in combination with ifosfamide.', NULL, 'Due to the potential for additive effects, centrally-acting agents should be used with caution in combination with ifosfamide. If ifosfamide-induced encephalopathy occurs, both ifosfamide and non-essential concomitant CNS agents should be discontinued. Supportive therapy should be initiated and maintained until complete resolution of neurotoxicity.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511157, 'Ifosfamide', 'Cytarabine', 'Moderate', 'The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.', NULL, 'Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.', NULL, 'Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers'' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511158, 'Ifosfamide', 'Cytarabine (liposomal)', 'Moderate', 'The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.', NULL, 'Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.', NULL, 'Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers'' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511159, 'Ifosfamide', 'Dacarbazine', 'Moderate', 'The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.', NULL, 'Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.', NULL, 'Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers'' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511160, 'Ifosfamide', 'Dexbrompheniramine', 'Moderate', 'Centrally-acting agents such as antiemetics, sedatives, narcotics, or antihistamines may add to the neurotoxic effects of ifosfamide. Administration of ifosfamide can cause CNS toxicity, which necessitates careful monitoring of the patient. Neurologic manifestations include somnolence, confusion, hallucinations, blurred vision, psychotic behavior, extrapyramidal symptoms, urinary incontinence, seizures, and in some instances, coma. There have also been reports of peripheral neuropathy. Ifosfamide neurotoxicity may occur within a few hours to a few days after initial administration and typically resolves within 48 to 72 hours of ifosfamide discontinuation.', NULL, 'Due to the potential for additive effects, centrally-acting agents should be used with caution in combination with ifosfamide.', NULL, 'Due to the potential for additive effects, centrally-acting agents should be used with caution in combination with ifosfamide. If ifosfamide-induced encephalopathy occurs, both ifosfamide and non-essential concomitant CNS agents should be discontinued. Supportive therapy should be initiated and maintained until complete resolution of neurotoxicity.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511161, 'Ifosfamide', 'Dezocine', 'Moderate', 'Centrally-acting agents such as antiemetics, sedatives, narcotics, or antihistamines may add to the neurotoxic effects of ifosfamide. Administration of ifosfamide can cause CNS toxicity, which necessitates careful monitoring of the patient. Neurologic manifestations include somnolence, confusion, hallucinations, blurred vision, psychotic behavior, extrapyramidal symptoms, urinary incontinence, seizures, and in some instances, coma. There have also been reports of peripheral neuropathy. Ifosfamide neurotoxicity may occur within a few hours to a few days after initial administration and typically resolves within 48 to 72 hours of ifosfamide discontinuation.', NULL, 'Due to the potential for additive effects, centrally-acting agents should be used with caution in combination with ifosfamide.', NULL, 'Due to the potential for additive effects, centrally-acting agents should be used with caution in combination with ifosfamide. If ifosfamide-induced encephalopathy occurs, both ifosfamide and non-essential concomitant CNS agents should be discontinued. Supportive therapy should be initiated and maintained until complete resolution of neurotoxicity.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511162, 'Ifosfamide', 'Dicoumarol', 'Moderate', 'Limited data (from three patients) reveal enhanced anticoagulant activity (significantly increased INR) during chemotherapy with ifosfamide/mesna in patients previously stable on warfarin. The mechanism is not known, but is suspected to be displacement of warfarin from protein-binding sites by ifosfamide metabolites.', NULL, 'Careful and frequent monitoring of INR during coadministration is recommended.', NULL, 'Careful and frequent monitoring of INR during coadministration is recommended. Also, close monitoring is recommended when chemotherapeutic agents are discontinued, because anticoagulant effect may be decreased and the risk of thromboembolism increased. It may also be advisable to monitor patients on other anticoagulants.', 'Others', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511163, 'Ifosfamide', 'Dimenhydrinate', 'Moderate', 'Centrally-acting agents such as antiemetics, sedatives, narcotics, or antihistamines may add to the neurotoxic effects of ifosfamide. Administration of ifosfamide can cause CNS toxicity, which necessitates careful monitoring of the patient. Neurologic manifestations include somnolence, confusion, hallucinations, blurred vision, psychotic behavior, extrapyramidal symptoms, urinary incontinence, seizures, and in some instances, coma. There have also been reports of peripheral neuropathy. Ifosfamide neurotoxicity may occur within a few hours to a few days after initial administration and typically resolves within 48 to 72 hours of ifosfamide discontinuation.', NULL, 'Due to the potential for additive effects, centrally-acting agents should be used with caution in combination with ifosfamide.', NULL, 'Due to the potential for additive effects, centrally-acting agents should be used with caution in combination with ifosfamide. If ifosfamide-induced encephalopathy occurs, both ifosfamide and non-essential concomitant CNS agents should be discontinued. Supportive therapy should be initiated and maintained until complete resolution of neurotoxicity.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511164, 'Ifosfamide', 'Doxorubicin (liposomal)', 'Moderate', 'The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.', NULL, 'Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.', NULL, 'Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers'' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511165, 'Ifosfamide', 'Echinacea', 'Moderate', 'Coadministration with echinacea may alter the plasma concentrations and therapeutic effects of drugs that are substrates of CYP450 3A4. Echinacea appears to inhibit intestinal CYP450 3A4, which would lead to an increase in oral midazolam (a sensitive 3A4 substrate) bioavailability; however, plasma levels of midazolam following oral administration do not appear to be affected by echinacea. In contrast, it appears that echinacea may also induce hepatic CYP450 3A4; thereby increasing the hepatic clearance of drugs that are substrates of CYP450 3A4.', NULL, 'In general, patients should be advised to consult their healthcare provider before using any herbal or alternative medicines.', NULL, 'In general, patients should be advised to consult their healthcare provider before using any herbal or alternative medicines. If echinacea is prescribed with a drug that is a CYP450 3A4 substrate, the possibility of an altered (increased or decreased) therapeutic response should be considered. Patients should be monitored more closely following the addition or withdrawal of echinacea and the dosage of the CYP450 3A4 substrate adjusted as necessary.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511166, 'Ifosfamide', 'Efalizumab', 'Moderate', 'The use of efalizumab with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Efalizumab alone can cause serious infections requiring hospitalization, and the risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'The safety and efficacy of efalizumab in combination with other immunosuppressive agents or phototherapy have not been evaluated.', NULL, 'The safety and efficacy of efalizumab in combination with other immunosuppressive agents or phototherapy have not been evaluated. Patients receiving other immunosuppressive agents should not be treated with efalizumab because of the possibility of excessive immunosuppression. The duration of the period following treatment with efalizumab before one should consider starting other immunosuppressive therapy has not been evaluated.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511167, 'Ifosfamide', 'Enoxacin', 'Minor', 'Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics. The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.', NULL, '-', NULL, '-', 'Absorption', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511168, 'Ifosfamide', 'Ethchlorvynol', 'Moderate', 'Centrally-acting agents such as antiemetics, sedatives, narcotics, or antihistamines may add to the neurotoxic effects of ifosfamide. Administration of ifosfamide can cause CNS toxicity, which necessitates careful monitoring of the patient. Neurologic manifestations include somnolence, confusion, hallucinations, blurred vision, psychotic behavior, extrapyramidal symptoms, urinary incontinence, seizures, and in some instances, coma. There have also been reports of peripheral neuropathy. Ifosfamide neurotoxicity may occur within a few hours to a few days after initial administration and typically resolves within 48 to 72 hours of ifosfamide discontinuation.', NULL, 'Due to the potential for additive effects, centrally-acting agents should be used with caution in combination with ifosfamide.', NULL, 'Due to the potential for additive effects, centrally-acting agents should be used with caution in combination with ifosfamide. If ifosfamide-induced encephalopathy occurs, both ifosfamide and non-essential concomitant CNS agents should be discontinued. Supportive therapy should be initiated and maintained until complete resolution of neurotoxicity.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511169, 'Ifosfamide', 'Flurazepam', 'Moderate', 'Centrally-acting agents such as antiemetics, sedatives, narcotics, or antihistamines may add to the neurotoxic effects of ifosfamide. Administration of ifosfamide can cause CNS toxicity, which necessitates careful monitoring of the patient. Neurologic manifestations include somnolence, confusion, hallucinations, blurred vision, psychotic behavior, extrapyramidal symptoms, urinary incontinence, seizures, and in some instances, coma. There have also been reports of peripheral neuropathy. Ifosfamide neurotoxicity may occur within a few hours to a few days after initial administration and typically resolves within 48 to 72 hours of ifosfamide discontinuation.', NULL, 'Due to the potential for additive effects, centrally-acting agents should be used with caution in combination with ifosfamide.', NULL, 'Due to the potential for additive effects, centrally-acting agents should be used with caution in combination with ifosfamide. If ifosfamide-induced encephalopathy occurs, both ifosfamide and non-essential concomitant CNS agents should be discontinued. Supportive therapy should be initiated and maintained until complete resolution of neurotoxicity.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511170, 'Ifosfamide', 'Gatifloxacin', 'Minor', 'Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics. The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.', NULL, '-', NULL, '-', 'Absorption', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511171, 'Ifosfamide', 'Gentamicin', 'Moderate', 'The concurrent or sequential use of two or more potentially nephrotoxic or neurotoxic drugs may increase the risk of toxicity. Patients who are elderly, debilitated, dehydrated, or who have preexisting renal dysfunction may have a higher risk of developing adverse reactions.', NULL, 'Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.', NULL, 'Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511172, 'Ifosfamide', 'Grepafloxacin', 'Moderate', 'Based on in vitro inhibition data, coadministration with grepafloxacin may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by grepafloxacin.', NULL, 'Caution is advised if grepafloxacin must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised if grepafloxacin must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever grepafloxacin is added to or withdrawn from therapy.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511173, 'Ifosfamide', 'Halazepam', 'Moderate', 'Centrally-acting agents such as antiemetics, sedatives, narcotics, or antihistamines may add to the neurotoxic effects of ifosfamide. Administration of ifosfamide can cause CNS toxicity, which necessitates careful monitoring of the patient. Neurologic manifestations include somnolence, confusion, hallucinations, blurred vision, psychotic behavior, extrapyramidal symptoms, urinary incontinence, seizures, and in some instances, coma. There have also been reports of peripheral neuropathy. Ifosfamide neurotoxicity may occur within a few hours to a few days after initial administration and typically resolves within 48 to 72 hours of ifosfamide discontinuation.', NULL, 'Due to the potential for additive effects, centrally-acting agents should be used with caution in combination with ifosfamide.', NULL, 'Due to the potential for additive effects, centrally-acting agents should be used with caution in combination with ifosfamide. If ifosfamide-induced encephalopathy occurs, both ifosfamide and non-essential concomitant CNS agents should be discontinued. Supportive therapy should be initiated and maintained until complete resolution of neurotoxicity.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511174, 'Ifosfamide', 'Diamorphine', 'Moderate', 'Centrally-acting agents such as antiemetics, sedatives, narcotics, or antihistamines may add to the neurotoxic effects of ifosfamide. Administration of ifosfamide can cause CNS toxicity, which necessitates careful monitoring of the patient. Neurologic manifestations include somnolence, confusion, hallucinations, blurred vision, psychotic behavior, extrapyramidal symptoms, urinary incontinence, seizures, and in some instances, coma. There have also been reports of peripheral neuropathy. Ifosfamide neurotoxicity may occur within a few hours to a few days after initial administration and typically resolves within 48 to 72 hours of ifosfamide discontinuation.', NULL, 'Due to the potential for additive effects, centrally-acting agents should be used with caution in combination with ifosfamide.', NULL, 'Due to the potential for additive effects, centrally-acting agents should be used with caution in combination with ifosfamide. If ifosfamide-induced encephalopathy occurs, both ifosfamide and non-essential concomitant CNS agents should be discontinued. Supportive therapy should be initiated and maintained until complete resolution of neurotoxicity.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511175, 'Iloperidone', 'Ifosfamide', 'Moderate', 'Centrally-acting agents such as antiemetics, sedatives, narcotics, or antihistamines may add to the neurotoxic effects of ifosfamide. Administration of ifosfamide can cause CNS toxicity, which necessitates careful monitoring of the patient. Neurologic manifestations include somnolence, confusion, hallucinations, blurred vision, psychotic behavior, extrapyramidal symptoms, urinary incontinence, seizures, and in some instances, coma. There have also been reports of peripheral neuropathy. Ifosfamide neurotoxicity may occur within a few hours to a few days after initial administration and typically resolves within 48 to 72 hours of ifosfamide discontinuation.', NULL, 'Due to the potential for additive effects, centrally-acting agents should be used with caution in combination with ifosfamide.', NULL, 'Due to the potential for additive effects, centrally-acting agents should be used with caution in combination with ifosfamide. If ifosfamide-induced encephalopathy occurs, both ifosfamide and non-essential concomitant CNS agents should be discontinued. Supportive therapy should be initiated and maintained until complete resolution of neurotoxicity.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511176, 'Imatinib', 'Ifosfamide', 'Moderate', 'Coadministration with imatinib may increase the plasma concentrations of drugs that are substrates of CYP450 2C9, 2D6 and/or 3A4. The mechanism is decreased clearance due to inhibition of these isoenzymes by imatinib.', NULL, 'Caution is advised when imatinib is used concomitantly with drugs that undergo metabolism by CYP450 2C9, 2D6 and/or 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when imatinib is used concomitantly with drugs that undergo metabolism by CYP450 2C9, 2D6 and/or 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever imatinib is added to or withdrawn from therapy.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511177, 'Imipramine', 'Ifosfamide', 'Moderate', 'Centrally-acting agents such as antiemetics, sedatives, narcotics, or antihistamines may add to the neurotoxic effects of ifosfamide. Administration of ifosfamide can cause CNS toxicity, which necessitates careful monitoring of the patient. Neurologic manifestations include somnolence, confusion, hallucinations, blurred vision, psychotic behavior, extrapyramidal symptoms, urinary incontinence, seizures, and in some instances, coma. There have also been reports of peripheral neuropathy. Ifosfamide neurotoxicity may occur within a few hours to a few days after initial administration and typically resolves within 48 to 72 hours of ifosfamide discontinuation.', NULL, 'Due to the potential for additive effects, centrally-acting agents should be used with caution in combination with ifosfamide.', NULL, 'Due to the potential for additive effects, centrally-acting agents should be used with caution in combination with ifosfamide. If ifosfamide-induced encephalopathy occurs, both ifosfamide and non-essential concomitant CNS agents should be discontinued. Supportive therapy should be initiated and maintained until complete resolution of neurotoxicity.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511178, 'Infliximab', 'Ifosfamide', 'Major', 'The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Serious infections and sepsis, including fatalities, have been reported with the use of TNF blockers, particularly in patients on concomitant immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids. Concomitant use of TNF blockers with other immunosuppressants such as azathioprine or mercaptopurine may also increase the risk of a rare and often fatal cancer of white blood cells known as hepatosplenic T-Cell lymphoma (HSTCL).', NULL, 'Patients receiving a TNF blocker alone or with other immunosuppressive or myelosuppressive agents should be monitored closely for the development of infections.', NULL, 'Patients receiving a TNF blocker alone or with other immunosuppressive or myelosuppressive agents should be monitored closely for the development of infections. TNF blocker therapy should be discontinued if a serious infection or sepsis occurs. Close monitoring for signs and symptoms of HSTCL (e.g., splenomegaly, hepatomegaly, abdominal pain, persistent fever, night sweats, weight loss) is also recommended during use of TNF blockers, particularly in combination with other immunosuppressants such as azathioprine and mercaptopurine.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511179, 'Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)', 'Ifosfamide', 'Moderate', 'The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.', NULL, 'In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.', NULL, 'In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin''s disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.', 'Antagonism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511180, 'Influenza A virus A/Vietnam/1194/2004 (H5N1) antigen (formaldehyde inactivated)', 'Ifosfamide', 'Moderate', 'The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.', NULL, 'In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.', NULL, 'In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin''s disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.', 'Antagonism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511181, 'Interferon alfa-2a, Recombinant', 'Ifosfamide', 'Moderate', 'The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.', NULL, 'Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.', NULL, 'Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers'' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511182, 'Iodipamide', 'Ifosfamide', 'Major', 'Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511183, 'Iodixanol', 'Ifosfamide', 'Major', 'Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511184, 'Ioversol', 'Ifosfamide', 'Major', 'Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511185, 'Ioxilan', 'Ifosfamide', 'Major', 'Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511186, 'Ifosfamide', 'Lactobacillus acidophilus', 'Moderate', 'Probiotic use during immunosuppressant or intense antineoplastic therapy may theoretically increase the risk of infections from the live microorganisms contained in probiotic products. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.', NULL, 'Caution is advised when probiotics are used during immunosuppressant or intense antineoplastic therapy.', NULL, 'Caution is advised when probiotics are used during immunosuppressant or intense antineoplastic therapy. It may be advisable to avoid using probiotics, particularly products containing saccharomyces boulardii, in patients who are significantly immunosuppressed.', 'Others', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511187, 'Ifosfamide', 'Levacetylmethadol', 'Moderate', 'Centrally-acting agents such as antiemetics, sedatives, narcotics, or antihistamines may add to the neurotoxic effects of ifosfamide. Administration of ifosfamide can cause CNS toxicity, which necessitates careful monitoring of the patient. Neurologic manifestations include somnolence, confusion, hallucinations, blurred vision, psychotic behavior, extrapyramidal symptoms, urinary incontinence, seizures, and in some instances, coma. There have also been reports of peripheral neuropathy. Ifosfamide neurotoxicity may occur within a few hours to a few days after initial administration and typically resolves within 48 to 72 hours of ifosfamide discontinuation.', NULL, 'Due to the potential for additive effects, centrally-acting agents should be used with caution in combination with ifosfamide.', NULL, 'Due to the potential for additive effects, centrally-acting agents should be used with caution in combination with ifosfamide. If ifosfamide-induced encephalopathy occurs, both ifosfamide and non-essential concomitant CNS agents should be discontinued. Supportive therapy should be initiated and maintained until complete resolution of neurotoxicity.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511188, 'Ifosfamide', 'Lomefloxacin', 'Minor', 'Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics. The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.', NULL, '-', NULL, '-', 'Absorption', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511189, 'Ifosfamide', 'Lyme disease vaccine (recombinant OspA)', 'Moderate', 'The administration of Lyme disease vaccine to immunosuppressed patients may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.', NULL, 'The manufacturer suggests considering deferral of vaccination against Lyme disease until 3 months after discontinuation of immunosuppressive therapy.', NULL, 'The manufacturer suggests considering deferral of vaccination against Lyme disease until 3 months after discontinuation of immunosuppressive therapy. Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison''s disease).', 'Others', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511190, 'Ifosfamide', 'Melatonin', 'Moderate', 'Centrally-acting agents such as antiemetics, sedatives, narcotics, or antihistamines may add to the neurotoxic effects of ifosfamide. Administration of ifosfamide can cause CNS toxicity, which necessitates careful monitoring of the patient. Neurologic manifestations include somnolence, confusion, hallucinations, blurred vision, psychotic behavior, extrapyramidal symptoms, urinary incontinence, seizures, and in some instances, coma. There have also been reports of peripheral neuropathy. Ifosfamide neurotoxicity may occur within a few hours to a few days after initial administration and typically resolves within 48 to 72 hours of ifosfamide discontinuation.', NULL, 'Due to the potential for additive effects, centrally-acting agents should be used with caution in combination with ifosfamide.', NULL, 'Due to the potential for additive effects, centrally-acting agents should be used with caution in combination with ifosfamide. If ifosfamide-induced encephalopathy occurs, both ifosfamide and non-essential concomitant CNS agents should be discontinued. Supportive therapy should be initiated and maintained until complete resolution of neurotoxicity.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511191, 'Ifosfamide', 'Meprobamate', 'Moderate', 'Centrally-acting agents such as antiemetics, sedatives, narcotics, or antihistamines may add to the neurotoxic effects of ifosfamide. Administration of ifosfamide can cause CNS toxicity, which necessitates careful monitoring of the patient. Neurologic manifestations include somnolence, confusion, hallucinations, blurred vision, psychotic behavior, extrapyramidal symptoms, urinary incontinence, seizures, and in some instances, coma. There have also been reports of peripheral neuropathy. Ifosfamide neurotoxicity may occur within a few hours to a few days after initial administration and typically resolves within 48 to 72 hours of ifosfamide discontinuation.', NULL, 'Due to the potential for additive effects, centrally-acting agents should be used with caution in combination with ifosfamide.', NULL, 'Due to the potential for additive effects, centrally-acting agents should be used with caution in combination with ifosfamide. If ifosfamide-induced encephalopathy occurs, both ifosfamide and non-essential concomitant CNS agents should be discontinued. Supportive therapy should be initiated and maintained until complete resolution of neurotoxicity.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511192, 'Ifosfamide', 'Mesoridazine', 'Moderate', 'Centrally-acting agents such as antiemetics, sedatives, narcotics, or antihistamines may add to the neurotoxic effects of ifosfamide. Administration of ifosfamide can cause CNS toxicity, which necessitates careful monitoring of the patient. Neurologic manifestations include somnolence, confusion, hallucinations, blurred vision, psychotic behavior, extrapyramidal symptoms, urinary incontinence, seizures, and in some instances, coma. There have also been reports of peripheral neuropathy. Ifosfamide neurotoxicity may occur within a few hours to a few days after initial administration and typically resolves within 48 to 72 hours of ifosfamide discontinuation.', NULL, 'Due to the potential for additive effects, centrally-acting agents should be used with caution in combination with ifosfamide.', NULL, 'Due to the potential for additive effects, centrally-acting agents should be used with caution in combination with ifosfamide. If ifosfamide-induced encephalopathy occurs, both ifosfamide and non-essential concomitant CNS agents should be discontinued. Supportive therapy should be initiated and maintained until complete resolution of neurotoxicity.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1511193, 'Ifosfamide', 'Methdilazine', 'Moderate', 'Centrally-acting agents such as antiemetics, sedatives, narcotics, or antihistamines may add to the neurotoxic effects of ifosfamide. Administration of ifosfamide can cause CNS toxicity, which necessitates careful monitoring of the patient. Neurologic manifestations include somnolence, confusion, hallucinations, blurred vision, psychotic behavior, extrapyramidal symptoms, urinary incontinence, seizures, and in some instances, coma. There have also been reports of peripheral neuropathy. Ifosfamide neurotoxicity may occur within a few hours to a few days after initial administration and typically resolves within 48 to 72 hours of ifosfamide discontinuation.', NULL, 'Due to the potential for additive effects, centrally-acting agents should be used with caution in combination with ifosfamide.', NULL, 'Due to the potential for additive effects, centrally-acting agents should be used with caution in combination with ifosfamide. If ifosfamide-induced encephalopathy occurs, both ifosfamide and non-essential concomitant CNS agents should be discontinued. Supportive therapy should be initiated and maintained until complete resolution of neurotoxicity.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317477);
